



NIST Micronutrients Measurement Quality Assurance Program Summer 2014 Comparability Studies

Results for Round Robin LXXVI
Fat-Soluble Vitamins and Carotenoids in Human Serum
and Round Robin 41 Ascorbic Acid in Human Serum



David L. Duewer
Jeanice B. Thomas

This publication is available free of charge from:
<http://dx.doi.org/10.6028/NIST.IR.7880-44>



NISTIR 7880-44

**NIST Micronutrients Measurement
Quality Assurance Program
Summer 2014
Comparability Studies**

Results for Round Robin LXXVI
Fat-Soluble Vitamins and Carotenoids in Human Serum
and Round Robin 41 Ascorbic Acid in Human Serum

David L. Duewer
Jeanice B. Thomas
*Chemical Sciences Division
Materials Measurement Laboratory*

This publication is available free of charge from:
<http://dx.doi.org/10.6028/NIST.IR.7880-44>

June 2015



U.S. Department of Commerce
Penny Pritzker, Secretary

National Institute of Standards and Technology
Willie E. May, Under Secretary of Commerce for Standards and Technology and Director

(This page intentionally blank)

Abstract

The National Institute of Standards and Technology coordinates the Micronutrients Measurement Quality Assurance Program (MMQAP) for laboratories that measure fat- and water-soluble vitamins and carotenoids in human serum and plasma. This report describes the design of and results for the Summer 2014 MMQAP measurement comparability improvement studies: 1) Round Robin LXXVI Fat-Soluble Vitamins and Carotenoids in Human Serum and 2) Round Robin 41 Total Ascorbic Acid in Human Serum. To avoid increasing participation fees, the overhead costs for these programs were minimized by shipping the materials in January 2014 together with the samples for FSV Round Robin LXXV and VC Round Robin 40. Participants were requested not to analyze any of the Summer samples before June 1, 2014 but to provide their measurement results by September 15, 2014. Participants were reminded of the due-date by e-mail on August 4, 2014.

Keywords

Human Serum
Retinol, α -Tocopherol, γ -Tocopherol, Total and *Trans*- β -Carotene
Total Ascorbic Acid

Table of Contents

| | |
|---|-----|
| Abstract | iii |
| Keywords | iii |
| Table of Contents | iv |
| Introduction | 1 |
| Round Robin LXXVI: Fat-Soluble Vitamins and Carotenoids in Human Serum | 1 |
| Round Robin 41: Vitamin C in Human Serum | 2 |
| References | 3 |
| | |
| Appendix A. Shipping Package Inserts for RR76 | A1 |
| Appendix B. Final Report for RR76 | B1 |
| Appendix C. All-Lab Report for RR76 | C1 |
| Appendix D. Representative Individualized Report for RR76 | D1 |
| Appendix E. Shipping Package Inserts for RR41 | E1 |
| Appendix F. Final Report for RR41 | F1 |
| Appendix G. “All-Lab Report” for RR41 | G1 |
| Appendix H. Representative “Individualized Report” for RR41 | H1 |

Introduction

Beginning in 1988, the National Institute of Standards and Technology (NIST) has coordinated the Micronutrients Measurement Quality Assurance Program (MMQAP) for laboratories that measure fat- and water-soluble vitamins and carotenoids in human serum and plasma. The MMQAP provides participants with measurement comparability assessment through use of interlaboratory studies, Standard Reference Materials (SRMs) and control materials, and methods development and validation. Serum-based samples with assigned values for the target analytes (retinol, alpha-tocopherol, gamma/beta-tocopherol, *trans*- and total beta-carotene, and total ascorbic acid) and performance-evaluation standards are distributed by NIST to laboratories for analysis.

Participants use the methodology of their choice to determine analyte content in the control and study materials. Participants provide their data to NIST, where it is compiled and evaluated for trueness relative to the NIST value, within-laboratory precision, and concordance within the participant community. NIST provides the participants with a technical summary report concerning their performance for each exercise and suggestions for methods development and refinement. Participants who have concerns regarding their laboratory's performance are encouraged to consult with the MMQAP coordinators.

All MMQAP interlaboratory studies consist of individual units of batch-prepared samples that are distributed to each participant. For historical reasons these studies are referred to as "Round Robins". The MMQAP program and the nature of its studies are described elsewhere. [1,2]

Round Robin LXXVI: Fat-Soluble Vitamins and Carotenoids in Human Serum

Participants in the MMQAP Fat-Soluble Vitamins and Carotenoids in Human Serum Round Robin LXXVI comparability study (hereafter referred to as RR76) received one lyophilized and four liquid-frozen human serum test samples for analysis. Unless multiple vials were previously requested, participants received one vial of each serum. These sera were shipped on dry ice to participants in January 2014 in the same shipping package as the RR75 materials but in separate clearly labeled plastic bags. Participants were requested not to analyze any of the RR76 samples before June 1, 2014 but to provide their measurement results by September 15, 2014. The communication materials included in the sample shipment are provided in Appendix A.

Participants are requested to report values for all fat-soluble vitamin-related analytes that are of interest to their organizations. Not all participants report values for the target analytes, and many participants report values for non-target analytes.

The final report delivered to every participant in RR76 consists of three documents:

- A cover letter for the current study, a brief description of the other two documents, and a discussion of our analysis of the overall results that may be of broad interest. This cover letter is reproduced as Appendix B.
- The "All-Lab Report" that lists all of the reported measurement results, a number of consensus statistics for analytes reported by more than one participant, and the mean median and pooled SD from any prior distributions of the serum. This report also provides a

numerical “score card” for each participant’s measurement comparability for the more commonly reported analytes. This All-Lab Report is reproduced as Appendix C.

- An “Individualized Report” that graphically analyzes each participant’s results for all analytes reported by at least five participants. This report also provides a graphical summary of their measurement comparability. The graphical tools used in the Individualized Report are described in detail elsewhere [3]. An example Individualized Report is reproduced as Appendix D.

Round Robin 41: Vitamin C in Human Serum

Participants in the MMQAP Vitamin C in Human Serum Round Robin 40 comparability study (hereafter referred to as RR41) received four frozen serum test samples and two frozen control sera. Unless multiple vials were previously requested, participants received one vial of each material. These materials were shipped on dry ice to participants in January 2014 in the same shipping package as the RR40 materials but in separate clearly labeled plastic bags. Participants were requested not to analyze any of the RR41 samples before June 1, 2014 but to provide their measurement results by September 15, 2014. The communication materials included in the sample shipment are provided in Appendix E.

The test and control serum materials were prepared by adding equal volumes of 10 % metaphosphoric acid (MPA) to human serum that had been spiked with ascorbic acid. While these samples contain some dehydroascorbic acid, its content is variable. Therefore, the participants report only total ascorbic acid (TAA, ascorbic acid plus dehydroascorbic acid).

The final report delivered to every participant in RR41 consists of three documents:

- A cover letter for the current study, a brief description of the other two documents, and a discussion of our analysis of overall results that may be of broad interest. This cover letter is reproduced as Appendix F.
- The “All-Lab Report” that summarizes all of the reported measurement results and provides several consensus statistics. This All-Lab Report is reproduced as Appendix G.
- An “Individualized Report” that graphically analyzes each participant’s results for TAA, including a graphical summary of their measurement comparability. The graphical tools used in the Individualized Report are described in detail elsewhere [3]. An example Individualized Report is reproduced as Appendix H.

References

- 1 Duewer DL, Brown Thomas J, Kline MC, MacCrehan WA, Schaffer R, Sharpless KE, May WE, Crowell JA. NIST/NCI Micronutrients Measurement Quality Assurance Program: Measurement Repeatabilities and Reproducibilities for Fat-Soluble Vitamin-Related Compounds in Human Sera. *Anal Chem* 1997;69(7):1406-1413.
- 2 Margolis SA, Duewer DL. Measurement Of Ascorbic Acid in Human Plasma and Serum: Stability, Intralaboratory Repeatability, and Interlaboratory Reproducibility. *Clin Chem* 1996;42(8):1257-1262.
- 3 Duewer DL, Kline MC, Sharpless KE, Brown Thomas J, Gary KT, Sowell AL. Micronutrients Measurement Quality Assurance Program: Helping Participants Use Interlaboratory Comparison Exercise Results to Improve Their Long-Term Measurement Performance. *Anal Chem* 1999;71(9):1870-1878.

Appendix A. Shipping Package Inserts for RR76

The following items were included in each package shipped to an RR76 participant:

- Combined cover letter for Round Robin LXXV (RR75) and RR76. See Appendix A in NISTIR-43.
- Datasheet for RR76. This was enclosed in the same sealed waterproof bag that contained the cover letter and the data sheet for RR75.
- Packing List and Shipment Receipt Confirmation Form for RR76.

This RR76 samples were enclosed in a bubble-wrapped sealed plastic bag that was labeled:

NIST MMQAP-FSV: RR LXXVI
Micronutrients Measurement Fat-Soluble
Vitamin
Quality Assurance Program
Summer 2014 Samples
Analyze after: **June 1, 2014**
Results due on or before:
September 15, 2014

The packing list was placed at the top of the shipping box, between the cardboard covering and the foam insulation.

Participant #: _____

Date: _____

Round Robin LXXVI: Human Sera
NIST Micronutrients Measurement Quality Assurance Program

| Analyte | 407 | 408 | 409 | 410 | 411 | Units* |
|---------------------------------|-----|-----|-----|-----|-----|--------|
| total retinol | | | | | | |
| trans-retinol | | | | | | |
| retinyl palmitate | | | | | | |
| α-tocopherol | | | | | | |
| γ/β-tocopherol | | | | | | |
| δ-tocopherol | | | | | | |
| total β-carotene | | | | | | |
| trans-β-carotene | | | | | | |
| total cis-β-carotene | | | | | | |
| total α-carotene | | | | | | |
| total lycopene | | | | | | |
| trans-lycopene | | | | | | |
| total β-cryptoxanthin | | | | | | |
| total α-cryptoxanthin | | | | | | |
| total lutein | | | | | | |
| total zeaxanthin | | | | | | |
| total lutein&zeaxanthin | | | | | | |
| total coenzyme Q10 | | | | | | |
| ubiquinol (QH ₂) | | | | | | |
| ubiquinone (Qox) | | | | | | |
| phylloquinone (K ₁) | | | | | | |
| 25-hydroxyvitamin D | | | | | | |
| Phytoene | | | | | | |
| Phytofluene | | | | | | |
| | | | | | | |
| | | | | | | |

* we prefer µg/mL

Were the samples frozen when received? Yes | No

Comments:

Mail: M²QAP
 NIST, Stop 8392
 Gaithersburg, MD 20899-8392

Please return results by
15-Sep-2014
 A2

Fax: 301-977-0685
 Email: David.Duewer@NIST.gov

Participant #: _____

Date: _____

Fat-Soluble Vitamins Round Robin LXXVI
NIST Micronutrients Measurement Quality Assurance Program

Packing List and Shipment Receipt Confirmation Form

This box contains: one vial each of the following five FSV M²QAP sera

| Serum | Form | Reconstitute? | Vial/Cap |
|-------|---------------|---------------|---------------------|
| #407 | Lyophilized | Yes | 5 mL clear / silver |
| #408 | Liquid frozen | No | 3 mL amber / blue |
| #409 | Liquid frozen | No | 2 mL amber / gold |
| #410 | Liquid frozen | No | 2 mL amber / purple |
| #411 | Liquid frozen | No | 2 mL clear / black |

- Please**
- 1) Open the pack immediately
 - 2) Check that it contains all of the above samples
 - 3) Check if the vials are intact
 - 4) Store the sera at -20 °C or below until analysis
 - 5) Email (david.duewer@nist.gov) or fax (301-977-0685) us the following information:

1) Date this shipment arrived: _____

2) Are all five sera vials intact? Yes | No
If "No", which one(s) were damaged?

3) Was there any dry-ice left in cooler? Yes | No

4) Did the samples arrive frozen? Yes | No

5) At what temperature are you storing the serum samples? _____ °C

6) When do you anticipate analyzing these samples? _____

Your prompt return of this information is appreciated.

The M²QAP Gang

Appendix B. Final Report for RR76

The following three pages are the final report for RR76 as provided to all participants:

- Cover letter.
- An information sheet that:
 - describes the contents of the “All-Lab” report,
 - describes the content of the “Individualized” report,
 - describes the nature of the test samples and details their previous distributions, if any, and
 - summarizes aspects of the study that we believe may be of interest to the participants.

October 3, 2014



UNITED STATES DEPARTMENT OF COMMERCE
National Institute of Standards and Technology
Gaithersburg, Maryland 20899-8390

Dear Colleague:

Enclosed is the summary report of the results for Round Robin LXXVI (RR76) of the 2014 NIST Micronutrients Measurement Quality Assurance Program (MMQAP) for the fat-soluble vitamins and carotenoids in human serum. Included in this report are: 1) a summary of data and measurement comparability scores for all laboratories, 2) a detailed graphical analysis of your results; and 3) a graphical summary of your measurement comparability. RR76 (Sera 407 - 411) consisted of one vial of lyophilized serum and one vial each of four liquid-frozen serum samples. Details regarding the samples can be found in the enclosed report.

Your overall measurement comparability is summarized in the "Score Card" summary, page 6 of the All Lab Report. Combined results rated 1 to 3 are within 1 to 3 standard deviations of the assigned value, respectively; those rated 4 are >3 standard deviations from the assigned value. Similar information is presented graphically in the "target plots" that are the last page of your Individualized Report. If you have concerns regarding your laboratory's performance, please contact us for consultation.

If you returned your intent-to-participate form for the 2015 MMQAP, you should have received a confirmation receipt. Please notify us if you have not received your confirmation receipt.

Laboratories participating in the upcoming program will receive samples for the two fat-soluble vitamins and carotenoids in serum studies (RR LXXVII and LXXVIII) in February 2015. Please note that we will ship the samples for both studies at the same time in February. Results will be due in May 2015 for the first study and in September 2015 for the second study. We will send you a reminder in late July 2015 about the reporting deadline for the second study. Please contact us immediately if this schedule is problematic for your laboratory.

If you have questions or concerns regarding this report, please contact David Duewer at 301-976-3935; e-mail: david.duewer@nist.gov or me at 301-976-3120; e-mail: jbthomas@nist.gov; or fax: 301-977-0685.

Sincerely,

Jeanice Brown Thomas, M.B.A.
Research Chemist
Chemical Sciences Division
Material Measurement Laboratory

David L. Duewer, Ph.D.
Research Chemometrician
Chemical Sciences Division
Material Measurement Laboratory

Enclosures

The NIST MMQAP Round Robin LXXVI (RR76) report consists of:

| Page | All-Lab Report |
|------|---|
| 1-4 | A listing of all results and statistics for analytes reported by more than one participant. |
| 5 | The legend for the list of results and statistics. |
| 6 | The text Comparability Summary (“Score Card”) of measurement performance. |

| Page | Individualized Report |
|--------|--|
| 1 | Your values, the number of labs reporting values, and our assigned values. |
| 2 to n | “Four Plot” summaries of your current and past measurement performance, one page for each analyte you report that is also reported by at least eight other participants. |
| n+1 | The graphical Comparability Summary (target plot) of measurement performance. |

Samples. Five samples were distributed to each participant in RR76.

| Serum | Description | Prior Distributions |
|-------|--|--|
| 407 | Lyophilized, native, single-source, prepared in 1992. | #184:RR28-6/93, #319:RR59-3/96; #327:RR60-9/96 |
| 408 | Fresh-frozen, native, multi-donor, prepared in 2009. This is Level II of SRM 968e. | #358:RR66-9/09, #364:RR67-3/10, #374:RR69-3/11, #386:RR71-3/12; #399:RR74-9/13 |
| 409 | Fresh-frozen, native, single donor, prepared in 2011 | #383:RR71-3/12;#390:RR72-9/12 |
| 410 | Fresh-frozen, native, single donor, prepared in 2011 | #384:RR71-3/12 |
| 411 | Fresh-frozen, two donor, prepared in 2011. All analytes in this material are expected to be about half-way between those for sera 409 and 410. | #385:RR71-3/12;#396:RR73-3/13 |

Results

- 1) **Stability:** There have been no appreciable changes in either the level nor the variability in any analytes in the 22-year old lyophilized serum 407, the five-year old fresh-frozen SRM 968e serum 408, or the three-year old fresh-frozen sera 409, 410, and 411.
- 2) **Linear additivity:** Serum 411 was prepared as a 31:26 blend of the serum pools used to prepare sera 409 and 410. Assuming that the concentration of an analyte in the blend is the simple sum of the concentrations in the individual pools, the result for any analyte in the blended material is expected to be the weighted average of the results in the parent materials: Serum 411 = $((31 \times \#409) + (26 \times \text{Serum 410}))/57$.

Figure 1 plots values calculated from the sera 409 and 410 medians as a function of the medians of the serum 411 measurements. The measured and calculated values agree very well.

Therefore, if the result for any analyte in serum 411 is much different from the average of sera 409 and 410 results, you may want to carefully re-evaluate your measurement procedure for that analyte.




Figure 1: Measured vs Calculated Medians for the Blended Serum 411

The solid blue circles represent the {Measured, Calculated} median values for all RR76 analytes reported by at least five participants. The red line represents the ideal relationship: Estimated = Measured. The blue error-bars represent approximate 95 % confidence intervals on the medians, $\text{Median} \pm t_{95\%,n-1} \times \text{eSD}/\sqrt{n}$, where n is the number of participants reporting quantitative values for the analyte, eSD is estimated from the median absolute deviation from the median, and $t_{95\%,n-1}$ is the Student t 95 % confidence expansion factor.

Appendix C. “All-Lab Report” for RR76

The following six pages are the “All-Lab Report” for RR76 as provided to all participants, with two exceptions:

- the participant identifiers (Lab) have been altered and
- the order in which the participant results are listed has been altered.

The data summary in the “All-Lab Report” has been altered to ensure confidentiality of identification codes assigned to laboratories.

Round Robin LXXVI Laboratory Results

| Lab | Total Retinol, µg/mL | | | | | trans-Retinol, µg/mL | | | | | Retinyl Palmitate, µg/mL | | | | | α-Tocopherol, µg/mL | | | | | γ/β-Tocopherol, µg/mL | | | | |
|------------|----------------------|--------|--------|--------|--------|----------------------|-------|-------|-------|-------|--------------------------|-------|-------|-------|-------|---------------------|-------|-------|-------|-------|-----------------------|------|------|------|------|
| | 407 | 408 | 409 | 410 | 411 | 407 | 408 | 409 | 410 | 411 | 407 | 408 | 409 | 410 | 411 | 407 | 408 | 409 | 410 | 411 | 407 | 408 | 409 | 410 | 411 |
| FSV-BB | 0.342 | 0.477 | 0.444 | 0.452 | 0.438 | | | | | | 0.096 | 0.076 | 0.030 | 0.033 | 0.030 | 4.62 | 10.63 | 7.26 | 8.20 | 7.84 | 1.63 | 1.41 | 1.73 | 1.83 | 1.79 |
| FSV-BC | 0.339 | 0.491 | 0.428 | 0.432 | 0.441 | | | | | | | | | | | 4.30 | 10.90 | 7.50 | 8.40 | 7.70 | 1.60 | 1.10 | 1.60 | 1.70 | 1.70 |
| FSV-BD | 0.369 | 0.539 | 0.486 | 0.491 | 0.505 | | | | | | | | | | | 4.20 | 11.40 | 7.40 | 9.00 | 8.30 | | | | | |
| FSV-BE | 0.390 | 0.580 | 0.530 | 0.550 | 0.530 | | | | | | | | | | | 3.70 | 9.30 | 5.80 | 7.20 | 5.90 | | | | | |
| FSV-BFa | 0.350 | 0.460 | 0.450 | 0.450 | 0.420 | | | | | | 0.122 | 0.030 | 0.015 | 0.022 | 0.018 | 4.47 | 10.37 | 6.94 | 8.00 | 7.46 | 1.70 | 1.49 | 1.80 | 1.84 | 1.81 |
| FSV-BG | 0.362 | 0.496 | 0.459 | 0.465 | 0.462 | | | | | | | | | | | 4.22 | 11.13 | 6.93 | 8.58 | 7.28 | 1.31 | 1.30 | 1.51 | 1.70 | 1.50 |
| FSV-BH | 0.272 | 0.442 | 0.346 | 0.356 | 0.365 | | | | | | | | | | | 4.33 | 10.53 | 6.82 | 8.65 | 7.76 | 1.65 | 1.44 | 1.77 | 2.04 | 1.93 |
| FSV-BJ | 0.351 | 0.498 | 0.468 | 0.464 | 0.468 | | | | | | | | | | | 4.36 | 10.11 | 6.72 | 7.80 | 7.21 | | | | | |
| FSV-BK | 0.348 | 0.489 | 0.444 | 0.451 | 0.454 | | | | | | | | | | | 3.90 | 9.50 | 6.50 | 7.30 | 6.50 | | | | | |
| FSV-BL | 0.340 | 0.490 | 0.430 | 0.400 | 0.430 | | | | | | | | | | | 3.90 | 9.00 | 6.40 | 7.40 | 6.50 | | | | | |
| FSV-BM | 0.340 | 0.480 | 0.480 | 0.440 | 0.450 | | | | | | | | | | | 4.55 | 10.43 | 7.05 | 7.86 | 7.29 | | | | | |
| FSV-BN | 0.377 | 0.533 | 0.481 | 0.489 | 0.495 | | | | | | | | | | | 4.29 | 10.29 | 7.27 | 7.72 | 7.36 | | | | | |
| FSV-BO | 0.330 | 0.500 | 0.460 | 0.460 | 0.460 | | | | | | | | | | | 4.53 | 11.58 | 7.13 | 9.52 | 8.99 | | | | | |
| FSV-BR | 0.300 | 0.525 | 0.390 | 0.475 | 0.473 | | | | | | | | | | | | | | | | | | | | |
| FSV-BS | 0.345 | 0.499 | 0.471 | 0.483 | 0.467 | 0.345 | 0.499 | 0.471 | 0.483 | 0.467 | | | | | | 4.55 | 10.26 | 7.62 | na | 6.98 | 1.49 | 1.53 | 1.71 | na | 1.56 |
| FSV-BT | 0.389 | 0.524 | 0.450 | na | 0.595 | | | | | | | | | | | 4.90 | 10.48 | 8.28 | 9.31 | 7.50 | 1.68 | 1.32 | 1.91 | 2.09 | 1.71 |
| FSV-BU | 0.275 | 0.511 | 0.379 | 0.363 | 0.472 | | | | | | | | | | | 5.72 | 11.63 | 8.64 | 8.23 | 8.77 | 2.11 | 1.67 | 2.33 | 2.00 | 2.21 |
| FSV-BV | 0.405 | 0.491 | 0.519 | 0.380 | 0.471 | | | | | | 0.072 | 0.016 | 0.009 | 0.004 | 0.006 | 4.34 | 10.75 | 6.94 | 8.50 | 7.43 | 1.73 | 1.49 | 1.86 | 2.06 | 1.75 |
| FSV-BW | 0.570 | 0.500 | 0.500 | 0.520 | 0.430 | | | | | | | | | | | 4.63 | 10.35 | 7.42 | 7.97 | 7.99 | 1.73 | 1.41 | 1.77 | 1.88 | 1.88 |
| FSV-CD | 0.360 | 0.510 | 0.460 | 0.460 | 0.480 | | | | | | | | | | | 3.58 | 13.14 | 7.08 | 8.39 | 7.41 | | | | | |
| FSV-CE | 0.351 | 0.559 | 0.457 | 0.467 | 0.457 | | | | | | | | | | | 3.35 | 8.16 | 5.38 | 6.13 | 5.67 | 1.31 | 1.19 | 1.51 | 1.52 | 1.51 |
| FSV-CG | 0.313 | 0.425 | 0.397 | 0.387 | 0.393 | | | | | | 0.087 | 0.019 | 0.014 | 0.017 | 0.008 | 3.98 | 9.25 | 6.42 | 7.02 | 6.13 | 1.69 | 1.40 | 1.72 | 1.88 | 1.78 |
| FSV-CI | 0.312 | 0.458 | 0.342 | 0.377 | 0.410 | | | | | | | | | | | 4.31 | 10.23 | 6.84 | 8.20 | 7.40 | 1.64 | 1.47 | 1.83 | 1.92 | 1.83 |
| FSV-CO | 0.430 | 0.606 | 0.568 | 0.511 | 0.553 | | | | | | | | | | | 4.50 | 9.01 | 5.88 | 7.27 | 6.76 | 1.52 | 1.19 | 1.58 | 1.73 | 1.65 |
| FSV-CZ | 0.340 | 0.500 | 0.400 | 0.420 | 0.430 | | | | | | | | | | | 3.40 | 8.80 | 5.80 | 7.40 | 6.10 | | | | | |
| FSV-DD | 0.347 | 0.468 | 0.431 | 0.440 | 0.438 | | | | | | | | | | | | | | | | | | | | |
| FSV-DV | 0.347 | 0.468 | 0.431 | 0.440 | 0.438 | | | | | | | | | | | | | | | | | | | | |
| FSV-EE | 0.368 | 0.450 | 0.439 | 0.445 | 0.410 | | | | | | | | | | | | | | | | | | | | |
| FSV-FK | 0.368 | 0.450 | 0.439 | 0.445 | 0.410 | | | | | | | | | | | | | | | | | | | | |
| FSV-FZ | ≥0.342 | ≥0.451 | ≥0.447 | ≥0.455 | ≥0.463 | 0.342 | 0.451 | 0.447 | 0.455 | 0.463 | | | | | | | | | | | | | | | |
| FSV-GD | 0.343 | 0.496 | 0.454 | 0.449 | 0.454 | | | | | | | | | | | | | | | | | | | | |
| FSV-GE | 0.493 | 0.685 | 0.670 | 0.564 | 0.687 | | | | | | | | | | | | | | | | | | | | |
| N | 29 | 29 | 29 | 28 | 29 | 2 | 2 | 2 | 2 | 2 | 5 | 5 | 5 | 5 | 5 | 28 | 28 | 28 | 27 | 28 | 16 | 16 | 16 | 15 | 16 |
| Min | 0.272 | 0.425 | 0.342 | 0.356 | 0.365 | 0.342 | 0.451 | 0.447 | 0.455 | 0.463 | 0.059 | 0.016 | 0.009 | 0.004 | 0.006 | 3.35 | 8.16 | 5.30 | 6.13 | 5.67 | 1.31 | 1.10 | 1.51 | 1.52 | 1.50 |
| Median | 0.348 | 0.498 | 0.454 | 0.451 | 0.457 | 0.344 | 0.475 | 0.459 | 0.469 | 0.465 | 0.087 | 0.030 | 0.015 | 0.022 | 0.018 | 4.32 | 10.36 | 6.94 | 8.00 | 7.38 | 1.64 | 1.41 | 1.72 | 1.87 | 1.77 |
| Max | 0.570 | 0.685 | 0.670 | 0.564 | 0.687 | 0.345 | 0.499 | 0.471 | 0.483 | 0.467 | 0.122 | 0.076 | 0.030 | 0.033 | 0.030 | 12.37 | 33.53 | 23.61 | 21.62 | 17.76 | 2.11 | 1.67 | 2.33 | 2.09 | 2.21 |
| eSD | 0.027 | 0.031 | 0.039 | 0.041 | 0.034 | 0.022 | 0.021 | 0.003 | 0.007 | 0.015 | 0.022 | 0.021 | 0.003 | 0.007 | 0.015 | 0.34 | 0.89 | 0.67 | 0.85 | 0.64 | 0.11 | 0.13 | 0.14 | 0.19 | 0.10 |
| eCV | 8 | 6 | 8 | 9 | 7 | 26 | 70 | 20 | 32 | 82 | 26 | 70 | 20 | 32 | 82 | 8 | 9 | 10 | 11 | 9 | 7 | 9 | 8 | 10 | 5 |
| Npast | 36 | 31 | 29 | 31 | 31 | 8 | 8 | 0 | 0 | 0 | 10 | 7 | 5 | 6 | 6 | 38 | 30 | 27 | 29 | 30 | 21 | 18 | 15 | 16 | 17 |
| Medianpast | 0.366 | 0.507 | 0.462 | 0.470 | 0.474 | 0.409 | 0.481 | | | | 0.126 | 0.027 | 0.016 | 0.019 | 0.015 | 4.33 | 10.31 | 7.02 | 8.00 | 7.41 | 1.65 | 1.40 | 1.75 | 1.81 | 1.78 |
| SDpast | 0.031 | 0.041 | 0.029 | 0.034 | 0.035 | 0.030 | 0.050 | | | | 0.034 | 0.009 | 0.009 | 0.012 | 0.011 | 0.29 | 0.77 | 0.63 | 0.68 | 0.68 | 0.15 | 0.13 | 0.18 | 0.19 | 0.09 |
| NAV | 0.348 | 0.497 | 0.452 | 0.451 | 0.456 | 0.348 | 0.497 | 0.452 | 0.451 | 0.456 | 0.087 | 0.030 | 0.015 | 0.022 | 0.018 | 4.31 | 10.35 | 6.93 | 8.00 | 7.36 | 1.64 | 1.41 | 1.72 | 1.85 | 1.77 |
| NAU | 0.029 | 0.040 | 0.037 | 0.041 | 0.037 | 0.029 | 0.040 | 0.037 | 0.041 | 0.037 | 0.023 | 0.021 | 0.011 | 0.012 | 0.015 | 0.45 | 0.82 | 0.64 | 0.86 | 0.71 | 0.18 | 0.16 | 0.19 | 0.20 | 0.19 |

Q

Round Robin LXXVI Laboratory Results

| Lab | δ-Tocopherol, µg/mL | | | | | Total β-Carotene, µg/mL | | | | | trans-β-Carotene, µg/mL | | | | | Total cis-β-Carotene, µg/mL | | | | | Total α-Carotene, µg/mL | | | | |
|------------|---------------------|-------|-------|-------|-------|-------------------------|-------|-----------|-----------|-----------|-------------------------|-------|-------|-----------|-------|-----------------------------|-----------|-----------|-----------|-----------|-------------------------|-----------|-----------|-----------|-----------|
| | 407 | 408 | 409 | 410 | 411 | 407 | 408 | 409 | 410 | 411 | 407 | 408 | 409 | 410 | 411 | 407 | 408 | 409 | 410 | 411 | 407 | 408 | 409 | 410 | 411 |
| FSV-BB | 0.044 | 0.083 | 0.065 | 0.083 | 0.049 | 0.320 | 0.242 | 0.042 | 0.055 | 0.050 | 0.304 | 0.231 | 0.040 | 0.054 | 0.047 | 0.017 | 0.011 | 0.002 | 0.001 | 0.003 | 0.021 | 0.032 | 0.014 | 0.042 | 0.029 |
| FSV-BC | | | | | | 0.300 | 0.250 | 0.050 | 0.060 | 0.050 | | | | | | | | | | | 0.017 | 0.031 | 0.015 | 0.036 | 0.026 |
| FSV-BD | | | | | | 0.346 | 0.268 | 0.054 | 0.066 | 0.062 | | | | | | | | | | | <i>nq</i> | 0.025 | <i>nq</i> | 0.027 | <i>nq</i> |
| FSV-BE | | | | | | 0.288 | 0.234 | 0.034 | 0.045 | 0.036 | | | | | | | | | | | 0.006 | 0.025 | 0.017 | 0.040 | 0.022 |
| FSV-BFa | | | | | | 0.322 | 0.233 | 0.039 | 0.063 | 0.050 | | | | | | | | | | | | | | | |
| FSV-BG | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-BH | | | | | | 0.313 | 0.248 | 0.043 | 0.062 | 0.049 | | | | | | | | | | | 0.044 | 0.052 | 0.013 | 0.046 | 0.028 |
| FSV-BI | | | | | | 0.269 | 0.203 | 0.038 | 0.048 | 0.041 | | | | | | | | | | | 0.012 | 0.021 | 0.010 | 0.031 | 0.019 |
| FSV-BJ | | | | | | 0.416 | 0.193 | 0.105 | 0.126 | 0.118 | 0.416 | 0.193 | 0.105 | 0.126 | 0.118 | <i>nd</i> | <i>nd</i> | <i>nd</i> | <i>nd</i> | <i>nd</i> | 0.068 | 0.101 | 0.074 | 0.103 | 0.089 |
| FSV-BK | | | | | | 0.317 | 0.250 | 0.049 | <i>na</i> | 0.058 | 0.295 | 0.236 | 0.046 | <i>na</i> | 0.055 | 0.022 | 0.015 | 0.003 | <i>na</i> | 0.003 | 0.017 | 0.034 | 0.014 | <i>na</i> | 0.026 |
| FSV-BL | | | | | | 0.303 | 0.215 | 0.048 | 0.055 | 0.052 | | | | | | | | | | | 0.012 | 0.026 | 0.011 | 0.041 | 0.023 |
| FSV-BM | | | | | | 0.410 | 0.280 | 0.061 | 0.061 | 0.064 | | | | | | | | | | | 0.013 | 0.033 | 0.014 | 0.041 | 0.029 |
| FSV-BN | | | | | | 0.254 | 0.217 | 0.043 | 0.047 | 0.045 | | | | | | | | | | | 0.025 | 0.035 | 0.018 | 0.063 | 0.055 |
| FSV-BO | | | | | | 0.300 | 0.240 | <i>nq</i> | 0.053 | <i>nq</i> | | | | | | | | | | | <i>nq</i> | <i>nq</i> | <i>nq</i> | <i>nq</i> | <i>nq</i> |
| FSV-BP | | | | | | 0.274 | 0.281 | <0.03 | <0.03 | <0.03 | | | | | | | | | | | | | | | |
| FSV-BQ | | | | | | 0.279 | 0.221 | 0.039 | 0.052 | 0.044 | 0.258 | 0.208 | 0.037 | 0.049 | 0.041 | 0.021 | 0.011 | 0.005 | 0.005 | 0.005 | 0.013 | 0.030 | 0.010 | 0.036 | 0.022 |
| FSV-CG | 0.038 | 0.088 | 0.264 | 0.193 | 0.200 | 0.274 | 0.225 | 0.039 | 0.039 | 0.037 | | | | | | | | | | | 0.014 | 0.045 | 0.016 | 0.033 | 0.028 |
| FSV-CI | | | | | | 0.309 | 0.248 | 0.050 | 0.066 | 0.056 | | | | | | | | | | | 0.012 | 0.024 | 0.009 | 0.036 | 0.021 |
| FSV-CO | | | | | | 0.269 | 0.230 | 0.059 | 0.080 | 0.069 | | | | | | | | | | | | | | | |
| FSV-CZ | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-DD | | | | | | 0.699 | 0.233 | 0.027 | 0.044 | 0.034 | 0.266 | 0.213 | 0.038 | 0.053 | 0.044 | 0.036 | 0.029 | 0.006 | 0.008 | 0.006 | 0.026 | 0.032 | 0.017 | 0.048 | 0.032 |
| FSV-DV | | | | | | 0.304 | 0.234 | 0.046 | 0.062 | 0.055 | 5 | 5 | 5 | 4 | 5 | 4 | 4 | 4 | 3 | 4 | 14 | 15 | 14 | 14 | 14 |
| FSV-EE | | | | | | 0.302 | 0.242 | 0.044 | 0.061 | 0.050 | 0.258 | 0.193 | 0.037 | 0.049 | 0.041 | 0.017 | 0.011 | 0.002 | 0.001 | 0.003 | 0.006 | 0.021 | 0.009 | 0.027 | 0.019 |
| FSV-FK | | | | | | 1.278 | 0.923 | 0.499 | 0.258 | 0.268 | 0.295 | 0.213 | 0.040 | 0.053 | 0.047 | 0.022 | 0.013 | 0.004 | 0.005 | 0.004 | 0.016 | 0.032 | 0.014 | 0.041 | 0.027 |
| FSV-FZ | | | | | | 1.278 | 0.923 | 0.499 | 0.258 | 0.268 | 0.416 | 0.236 | 0.105 | 0.126 | 0.118 | 0.036 | 0.029 | 0.006 | 0.008 | 0.006 | 0.068 | 0.101 | 0.074 | 0.103 | 0.089 |
| FSV-GD | | | | | | 0.032 | 0.019 | 0.009 | 0.010 | 0.010 | 0.043 | 0.027 | 0.004 | 0.003 | 0.009 | 0.004 | 0.003 | 0.002 | | 0.002 | 0.005 | 0.008 | 0.004 | 0.007 | 0.007 |
| FSV-GE | | | | | | 11 | 8 | 20 | 17 | 21 | 15 | 13 | 11 | 6 | 19 | 18 | 23 | 55 | 45 | 45 | 33 | 25 | 30 | 18 | 25 |
| N | 2 | 2 | 2 | 2 | 2 | 27 | 21 | 17 | 18 | 20 | 7 | 7 | 5 | 5 | 6 | 5 | 5 | 0 | 0 | 8 | 17 | 16 | 13 | 15 | 16 |
| Min | 0.038 | 0.083 | 0.065 | 0.083 | 0.049 | 0.328 | 0.241 | 0.049 | 0.063 | 0.054 | 0.302 | 0.218 | 0.042 | 0.056 | 0.051 | 0.021 | 0.013 | | | 0.005 | 0.016 | 0.032 | 0.013 | 0.036 | 0.024 |
| Median | 0.041 | 0.085 | 0.165 | 0.138 | 0.124 | 0.047 | 0.030 | 0.010 | 0.013 | 0.009 | 0.031 | 0.024 | 0.003 | 0.007 | 0.004 | 0.004 | 0.004 | | | 0.005 | 0.005 | 0.011 | 0.005 | 0.007 | 0.005 |
| Max | 0.044 | 0.088 | 0.264 | 0.193 | 0.200 | | | | | | | | | | | | | | | | | | | | |
| eSD | | | | | | | | | | | | | | | | | | | | | | | | | |
| eCV | | | | | | | | | | | | | | | | | | | | | | | | | |
| Npast | 6 | 6 | 7 | 4 | 4 | | | | | | | | | | | | | | | | | | | | |
| Medianpast | 0.048 | 0.073 | 0.063 | 0.069 | 0.088 | | | | | | | | | | | | | | | | | | | | |
| SDpast | 0.009 | 0.024 | 0.043 | 0.052 | 0.042 | | | | | | | | | | | | | | | | | | | | |
| NAV | | | | | | 0.303 | 0.234 | 0.046 | 0.061 | 0.050 | 0.295 | 0.213 | 0.040 | 0.054 | 0.047 | 0.022 | 0.013 | 0.004 | 0.005 | 0.005 | 0.016 | 0.032 | 0.015 | 0.041 | 0.027 |
| NAU | | | | | | 0.044 | 0.035 | 0.010 | 0.012 | 0.011 | 0.043 | 0.027 | 0.008 | 0.009 | 0.009 | | | | | | 0.006 | 0.010 | 0.006 | 0.013 | 0.009 |

Round Robin LXXVI Laboratory Results

| Lab | Total Lycopene, µg/mL | | | | | trans-Lycopene, µg/mL | | | | | Total β-Cryptoxanthin, µg/mL | | | | | Total α-Cryptoxanthin, µg/mL | | | | | Total Lutein, µg/mL | | | | |
|------------|-----------------------|------|-------|-------|-------|-----------------------|-------|-------|-------|-------|------------------------------|-------|-------|-------|-------|------------------------------|-------|-------|-------|-------|---------------------|-------|-------|-------|-------|
| | 407 | 408 | 409 | 410 | 411 | 407 | 408 | 409 | 410 | 411 | 407 | 408 | 409 | 410 | 411 | 407 | 408 | 409 | 410 | 411 | 407 | 408 | 409 | 410 | 411 |
| FSV-BB | 0.156 | 0.54 | 0.152 | 0.292 | 0.214 | 0.088 | 0.263 | 0.073 | 0.133 | 0.105 | 0.053 | 0.051 | 0.164 | 0.022 | 0.098 | 0.022 | 0.020 | 0.020 | 0.012 | 0.016 | 0.082 | 0.083 | 0.073 | 0.087 | 0.080 |
| FSV-BC | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-BD | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-BE | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-BFa | 0.196 | 0.58 | 0.185 | 0.333 | 0.248 | 0.117 | 0.337 | 0.097 | 0.174 | 0.130 | 0.057 | 0.054 | 0.179 | 0.026 | 0.106 | | | | | | 0.066 | 0.080 | 0.058 | 0.068 | 0.069 |
| FSV-BG | 0.198 | 0.71 | 0.164 | 0.290 | 0.216 | | | | | | 0.060 | 0.060 | 0.182 | 0.023 | 0.104 | | | | | | 0.071 | 0.110 | 0.108 | 0.095 | 0.109 |
| FSV-BH | 0.170 | 0.59 | 0.148 | 0.342 | 0.227 | | | | | | 0.049 | 0.055 | 0.194 | 0.023 | 0.120 | | | | | | | | | | |
| FSV-BI | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-BJ | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-BK | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-BL | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-BM | 0.206 | 0.81 | 0.202 | 0.431 | 0.292 | | | | | | 0.054 | 0.053 | 0.183 | 0.017 | 0.107 | | | | | | 0.080 | 0.106 | 0.104 | 0.089 | 0.093 |
| FSV-BN | 0.136 | 0.43 | 0.133 | 0.245 | 0.197 | | | | | | 0.059 | 0.048 | 0.170 | 0.016 | 0.098 | | | | | | | | | | |
| FSV-BO | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-BR | 0.210 | 0.57 | 0.212 | 0.342 | 0.280 | 0.168 | 0.408 | 0.165 | 0.251 | 0.209 | 0.095 | 0.108 | 0.186 | 0.076 | 0.143 | 0.012 | 0.018 | 0.010 | na | 0.011 | 0.132 | 0.136 | 0.130 | 0.137 | 0.134 |
| FSV-BS | 0.102 | 0.35 | 0.111 | na | 0.152 | 0.092 | 0.312 | 0.096 | na | 0.135 | 0.039 | 0.046 | 0.096 | na | 0.064 | | | | | | 0.076 | 0.086 | 0.076 | na | 0.095 |
| FSV-BT | 0.184 | 0.58 | 0.189 | 0.368 | 0.271 | | | | | | 0.056 | 0.053 | 0.179 | 0.019 | 0.109 | | | | | | | | | | |
| FSV-BU | 0.232 | 0.68 | 0.235 | 0.345 | 0.297 | | | | | | 0.040 | 0.033 | 0.167 | 0.009 | 0.080 | | | | | | | | | | |
| FSV-BV | 0.168 | 0.61 | 0.161 | 0.281 | 0.247 | | | | | | 0.050 | na | 0.160 | na | 0.100 | na | na | na | na | na | | | | | |
| FSV-BW | 0.210 | 0.75 | 0.230 | 0.390 | 0.330 | | | | | | | | | | | | | | | | | | | | |
| FSV-CD | 0.171 | 0.55 | 0.166 | 0.294 | 0.218 | 0.091 | 0.279 | 0.077 | 0.139 | 0.102 | 0.058 | 0.063 | 0.155 | 0.034 | 0.097 | | | | | | 0.068 | 0.081 | 0.077 | 0.067 | 0.072 |
| FSV-CE | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-CG | 0.184 | 0.59 | 0.182 | 0.312 | 0.240 | | | | | | 0.050 | 0.049 | 0.144 | 0.021 | 0.088 | | | | | | | | | | |
| FSV-CI | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-CO | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-CZ | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-DD | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-DV | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-EE | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-FK | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-FZ | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-GD | 0.158 | 0.56 | 0.156 | 0.291 | 0.227 | | | | | | | | | | | | | | | | | | | | |
| FSV-GE | | | | | | | | | | | | | | | | | | | | | | | | | |
| N | 15 | 15 | 15 | 14 | 15 | 5 | 5 | 5 | 4 | 5 | 13 | 12 | 13 | 11 | 13 | 2 | 2 | 2 | 1 | 2 | 7 | 7 | 7 | 6 | 7 |
| Min | 0.102 | 0.35 | 0.111 | 0.245 | 0.152 | 0.088 | 0.263 | 0.073 | 0.133 | 0.102 | 0.039 | 0.033 | 0.096 | 0.009 | 0.064 | 0.012 | 0.018 | 0.010 | 0.011 | 0.011 | 0.066 | 0.080 | 0.058 | 0.067 | 0.069 |
| Median | 0.184 | 0.58 | 0.166 | 0.323 | 0.240 | 0.092 | 0.312 | 0.096 | 0.157 | 0.130 | 0.054 | 0.053 | 0.170 | 0.022 | 0.103 | 0.017 | 0.019 | 0.015 | 0.012 | 0.013 | 0.076 | 0.086 | 0.077 | 0.088 | 0.093 |
| Max | 0.232 | 0.81 | 0.235 | 0.431 | 0.330 | 0.168 | 0.408 | 0.165 | 0.251 | 0.209 | 0.095 | 0.108 | 0.194 | 0.076 | 0.143 | 0.022 | 0.020 | 0.020 | 0.016 | 0.016 | 0.132 | 0.136 | 0.130 | 0.137 | 0.134 |
| eSD | 0.033 | 0.06 | 0.028 | 0.046 | 0.038 | 0.006 | 0.049 | 0.028 | 0.031 | 0.038 | 0.006 | 0.007 | 0.018 | 0.006 | 0.010 | | | | | | 0.009 | 0.009 | 0.028 | 0.020 | 0.024 |
| eCV | 18 | 10 | 17 | 14 | 16 | 6 | 16 | 29 | 20 | 29 | 11 | 12 | 10 | 25 | 10 | | | | | | 12 | 10 | 37 | 23 | 26 |
| Npast | 20 | 15 | 12 | 13 | 15 | 8 | 7 | 6 | 6 | 7 | 18 | 15 | 12 | 13 | 15 | 4 | 5 | 6 | 4 | 4 | 12 | 7 | 5 | 4 | 6 |
| Medianpast | 0.186 | 0.60 | 0.174 | 0.327 | 0.238 | 0.100 | 0.292 | 0.081 | 0.148 | 0.120 | 0.058 | 0.053 | 0.168 | 0.027 | 0.100 | 0.026 | 0.026 | 0.025 | 0.013 | 0.019 | 0.080 | 0.092 | 0.093 | 0.076 | 0.086 |
| SDpast | 0.033 | 0.09 | 0.030 | 0.060 | 0.048 | 0.017 | 0.048 | 0.015 | 0.033 | 0.023 | 0.010 | 0.016 | 0.037 | 0.014 | 0.027 | 0.006 | 0.011 | 0.013 | 0.004 | 0.007 | 0.017 | 0.020 | 0.026 | 0.016 | 0.023 |
| NAV | 0.184 | 0.58 | 0.166 | 0.312 | 0.240 | 0.092 | 0.312 | 0.096 | 0.174 | 0.125 | 0.056 | 0.053 | 0.170 | 0.023 | 0.100 | | | | | | 0.076 | 0.086 | 0.077 | 0.089 | 0.093 |
| NAU | 0.046 | 0.12 | 0.042 | 0.070 | 0.057 | 0.016 | 0.057 | 0.028 | 0.052 | 0.030 | 0.013 | 0.013 | 0.036 | 0.006 | 0.022 | | | | | | 0.015 | 0.017 | 0.028 | 0.031 | 0.024 |

C4

Round Robin LXXVI Laboratory Results

| Lab | Total Zeaxanthin, µg/mL | | | | | Total Lutein&Zeaxanthin, µg/mL | | | | | Coenzyme Q10, µg/mL | | | | | Phylloquinone (K1), ng/mL | | | | | 25-hydroxyvitamin D, µg/mL | | | | | | | | | |
|------------|-------------------------|-------|-------|-------|-------|--------------------------------|-------|-------|-------|-------|---------------------|-------|------|-------|------|---------------------------|-------|-------|-------|-------|----------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| | 407 | 408 | 409 | 410 | 411 | 407 | 408 | 409 | 410 | 411 | 407 | 408 | 409 | 410 | 411 | 407 | 408 | 409 | 410 | 411 | 407 | 408 | 409 | 410 | 411 | | | | | |
| FSV-BB | 0.026 | 0.046 | 0.049 | 0.031 | 0.039 | 0.108 | 0.128 | 0.122 | 0.119 | 0.119 | | | | | | 0.76 | 0.910 | 1.07 | 0.910 | 0.99 | 0.140 | 0.312 | 0.110 | 0.189 | 0.135 | | | | | |
| FSV-BC | | | | | | 0.100 | 0.137 | 0.118 | 0.112 | 0.116 | | | | | | 0.47 | 0.863 | 0.69 | 0.919 | 0.88 | | | | | | 0.006 | 0.012 | 0.006 | 0.004 | 0.005 |
| FSV-BD | | | | | | 0.094 | 0.114 | 0.101 | 0.088 | 0.153 | | | | | | | | | | | | | | | | | | | | |
| FSV-BE | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-BFa | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-BG | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-BH | 0.028 | 0.035 | 0.043 | 0.020 | 0.084 | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-BJ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-BK | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-BL | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-BM | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-BN | | | | | | 0.104 | 0.133 | 0.140 | 0.103 | 0.122 | | | | | | 0.63 | 0.908 | 0.92 | 0.874 | 0.91 | | | | | | 0.006 | 0.015 | 0.005 | 0.005 | 0.003 |
| FSV-BO | 0.008 | 0.015 | 0.012 | 0.020 | 0.018 | 0.088 | 0.121 | 0.116 | 0.109 | 0.111 | | | | | | | | | | | | | | | | | | | | |
| FSV-BR | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-BS | 0.072 | 0.075 | 0.088 | 0.067 | 0.079 | 0.204 | 0.211 | 0.218 | 0.204 | 0.213 | | | | | | 0.57 | 0.778 | 0.97 | na | 1.12 | | | | | | | | | | |
| FSV-BT | 0.021 | 0.028 | 0.038 | na | 0.034 | 0.097 | 0.114 | 0.114 | na | 0.129 | | | | | | | | | | | | | | | | | | | | |
| FSV-BU | | | | | | 0.085 | 0.119 | 0.122 | 0.101 | 0.116 | | | | | | | | | | | | | | | | | | | | |
| FSV-BV | | | | | | 0.115 | 0.111 | 0.126 | 0.091 | 0.111 | | | | | | 0.96 | 1.020 | 1.47 | 1.090 | 1.08 | | | | | | | | | | |
| FSV-BW | | | | | | 0.120 | 0.140 | 0.130 | 0.090 | 0.130 | | | | | | | | | | | | | | | | | | | | |
| FSV-CD | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-CE | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-CG | | | | | | 0.083 | 0.114 | 0.113 | 0.094 | 0.104 | | | | | | | | | | | | | | | | | | | | |
| FSV-CI | 0.015 | 0.020 | 0.033 | 0.011 | 0.022 | 0.083 | 0.101 | 0.110 | 0.078 | 0.094 | | | | | | 0.82 | 1.060 | 1.21 | 1.130 | 1.21 | 0.109 | 0.221 | 0.066 | 0.129 | 0.095 | | | | | |
| FSV-CO | | | | | | 0.094 | 0.120 | 0.125 | 0.101 | 0.119 | | | | | | 0.79 | 0.999 | 0.98 | 0.927 | 1.01 | | | | | | | | | | |
| FSV-CZ | | | | | | | | | | | | | | | | 0.74 | 0.921 | 1.08 | 0.931 | 0.97 | 0.110 | 0.290 | 0.100 | 0.130 | 0.120 | | | | | |
| FSV-DD | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-DV | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-EE | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-FK | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-FZ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-GD | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| FSV-GE | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| N | 6 | 6 | 6 | 5 | 6 | 13 | 13 | 13 | 12 | 13 | 9 | 9 | 9 | 8 | 9 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Min | 0.008 | 0.015 | 0.012 | 0.011 | 0.018 | 0.083 | 0.101 | 0.101 | 0.078 | 0.094 | 0.47 | 0.778 | 0.69 | 0.847 | 0.88 | 0.109 | 0.221 | 0.066 | 0.129 | 0.095 | 0.006 | 0.012 | 0.005 | 0.004 | 0.003 | | | | | |
| Median | 0.024 | 0.032 | 0.041 | 0.020 | 0.037 | 0.097 | 0.120 | 0.122 | 0.101 | 0.119 | 0.74 | 0.921 | 1.07 | 0.923 | 0.99 | 0.110 | 0.290 | 0.100 | 0.130 | 0.120 | 0.006 | 0.013 | 0.006 | 0.004 | 0.004 | | | | | |
| Max | 0.072 | 0.075 | 0.088 | 0.067 | 0.084 | 0.204 | 0.211 | 0.218 | 0.204 | 0.213 | 0.96 | 1.060 | 1.47 | 1.130 | 1.21 | 0.140 | 0.312 | 0.110 | 0.189 | 0.135 | 0.006 | 0.015 | 0.006 | 0.005 | 0.005 | | | | | |
| eSD | 0.010 | 0.019 | 0.012 | 0.013 | 0.025 | 0.017 | 0.012 | 0.012 | 0.015 | 0.012 | 0.11 | 0.086 | 0.15 | 0.046 | 0.12 | | | | | | | | | | | | | | | |
| eCV | 41 | 60 | 28 | 67 | 67 | 18 | 10 | 10 | 15 | 10 | 15 | 9 | 14 | 5 | 12 | | | | | | | | | | | | | | | |
| Npast | 13 | 8 | 7 | 0 | 9 | 17 | 16 | 12 | 14 | 15 | 5 | 8 | 9 | 9 | 8 | 0 | 0 | 0 | 0 | 0 | 7 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Medianpast | 0.022 | 0.028 | 0.044 | | 0.034 | 0.106 | 0.127 | 0.124 | 0.107 | 0.119 | 0.72 | 0.966 | 1.07 | 0.955 | 1.01 | | | | | | 0.004 | 0.016 | | | | | | | | |
| SDpast | 0.005 | 0.012 | 0.026 | | 0.014 | 0.018 | 0.032 | 0.031 | 0.044 | 0.035 | 0.10 | 0.122 | 0.12 | 0.052 | 0.07 | | | | | | 0.000 | 0.004 | | | | | | | | |
| NAV | 0.024 | 0.032 | 0.041 | 0.025 | 0.038 | 0.097 | 0.120 | 0.122 | 0.101 | 0.119 | 0.74 | 0.921 | 1.07 | 0.919 | 0.98 | 0.110 | 0.290 | 0.100 | 0.130 | 0.120 | | | | | | | | | | |
| NAU | 0.010 | 0.019 | 0.012 | 0.008 | 0.026 | 0.020 | 0.025 | 0.025 | 0.021 | 0.025 | 0.11 | 0.092 | 0.15 | 0.092 | 0.11 | | | | | | | | | | | | | | | |

Round Robin LXXVI Laboratory Results

Analytes Reported By One Laboratory

Values in µg/mL

| Analyte | Code | 407 | 408 | 409 | 410 | 411 |
|------------------|--------|-------|-------|-------|-------|-------|
| Phytofluene | FSV-BS | 0.091 | 0.327 | 0.113 | 0.197 | 0.162 |
| Total ζ-Carotene | FSV-BS | 0.082 | 0.157 | 0.095 | 0.120 | 0.110 |

Table Legend

| Term | Definition |
|-------------------------------|--|
| N | Number of (non-NIST) quantitative values reported for this analyte |
| Min | Minimum (non-NIST) quantitative value reported |
| Median | Median (non-NIST) quantitative value reported |
| Max | Maximum (non-NIST) quantitative value reported |
| SD | Adjusted median absolute deviation from the median of the non-NIST results |
| CV | Coefficient of Variation for (non-NIST) results: $100 \cdot SD / \text{Median}$ |
| N_{past} | Mean of N(s) from past RR(s) |
| $\text{Median}_{\text{past}}$ | Mean of Median(s) from past RR(s) |
| SD_{past} | Pooled SD from past RR(s) |
| NAV | NIST Assigned Value = Median for analytes reported by ≥ 5 labs |
| NAU | NIST Assigned Uncertainty = the maximum of $(0.05 \cdot \text{NAV}, SD, SD_{\text{past}}, eSD)$. The expected long-term SD, eSD, is defined in: Duewer et al., Anal Chem 1997;69(7):1406-1413. |
| <i>na</i> | Not analyzed |
| <i>nd</i> | Not detected (i.e., no detectable peak for analyte) |
| <i>nq</i> | Detected but not quantitatively determined |
| $\geq x$ | Concentration greater than or equal to x |
| <i>italics</i> | Not explicitly reported but calculated by NIST from reported values |

Round Robin LXXVI Laboratory Results

Comparability Summary

| Lab | TR | aT | g/bT | bC | tbC | aC | TLy | TbX | TLu | TZ | L&Z |
|---------|----|----|------|----|-----|----|-----|-----|-----|----|-----|
| FSV-BB | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| FSV-BC | 1 | | | | | | | | | | |
| FSV-BD | 2 | 1 | | | | | | | | | |
| FSV-BE | 3 | 2 | 2 | 1 | | | | | | | |
| FSV-BFa | 1 | 2 | | | | | | | | | |
| FSV-BG | 1 | 1 | 1 | 1 | | 1 | 1 | 1 | | | 1 |
| FSV-BH | 3 | 1 | 2 | 2 | | 1 | 1 | 1 | 1 | 1 | 1 |
| FSV-BJ | 1 | 1 | 1 | 1 | | 1 | 1 | 1 | 1 | | |
| FSV-BK | 1 | 1 | | | | | | | | | |
| FSV-BL | 1 | 1 | | | | | | | | | |
| FSV-BM | 1 | 2 | | | | | | | | | |
| FSV-BN | 1 | 1 | | 1 | | 3 | 2 | 1 | | | 1 |
| FSV-BO | 1 | 1 | | 1 | | 1 | 2 | 1 | 1 | 2 | 1 |
| FSV-BR | 2 | 2 | | | | | | | | | |
| FSV-BS | 1 | | | 4 | 4 | 4 | 1 | 4 | 3 | 4 | 4 |
| FSV-BT | 3 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 |
| FSV-BU | 2 | 2 | 1 | 1 | | 1 | 1 | 1 | | | 1 |
| FSV-BV | 2 | 3 | 3 | 2 | | 1 | 2 | 2 | | | 1 |
| FSV-BW | 4 | 1 | 1 | 1 | | 2 | 1 | | | | |
| FSV-CD | 1 | 1 | 1 | 1 | | | 2 | 1 | | | 1 |
| FSV-CE | 1 | 2 | | 2 | | | | | | | |
| FSV-CG | 2 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | | | 1 |
| FSV-CI | 2 | 2 | 1 | 2 | | 1 | | | 1 | 1 | 1 |
| FSV-CO | | 1 | 1 | 1 | | 1 | 1 | 1 | | | 1 |
| FSV-CZ | 3 | 2 | 1 | 2 | | | | | | | |
| FSV-DD | 1 | | | | | | | | | | |
| FSV-DV | 1 | 2 | | | | | | | | | |
| FSV-FK | 1 | 2 | | 4 | | | | | | | |
| FSV-FZ | 1 | 1 | 1 | 1 | | | | | | | |
| FSV-GD | 1 | 1 | 1 | 1 | 1 | 1 | 1 | | | | |
| FSV-GE | 4 | 4 | | 4 | | | | | | | |
| n | 30 | 28 | 16 | 22 | 5 | 15 | 15 | 13 | 7 | 6 | 13 |

| | TR | aT | g/bT | bC | tbC | aC | TLy | TbX | TLu | TZ | L&Z |
|-----|----|----|------|----|-----|----|-----|-----|-----|----|-----|
| % 1 | 60 | 54 | 75 | 68 | 80 | 80 | 67 | 69 | 86 | 67 | 92 |
| % 2 | 20 | 36 | 19 | 18 | 0 | 7 | 33 | 23 | 0 | 17 | 0 |
| % 3 | 13 | 7 | 6 | 0 | 0 | 7 | 0 | 0 | 14 | 0 | 0 |
| % 4 | 7 | 4 | 0 | 14 | 20 | 7 | 0 | 8 | 0 | 17 | 8 |

| Label | Definition |
|-------|------------------------------|
| Lab | Participant code |
| TR | Total Retinol |
| aT | α -Tocopherol |
| g/bT | γ/β -Tocopherol |
| bC | Total β -Carotene |
| tbC | trans- β -Carotene |
| aC | Total α -Carotene |
| TLy | Total Lycopene |
| TbX | Total β -Cryptoxanthin |
| TLu | Total Lutein |
| TZ | Total Zeaxanthin |
| L&Z | Total Lutein & Zeaxanthin |

- n | number of participants providing quantitative data
- % 1 | Percent of CS = 1 (within 1 SD of medians)
- % 2 | Percent of CS = 2 (within 2 SD of medians)
- % 3 | Percent of CS = 3 (within 3 SD of medians)
- % 4 | Percent of CS = 4 (3 or more SD from medians)

"Comparability Score"

The Comparability Score (CS) summarizes your measurement performance for a given analyte relative to the consensus medians in this study. CS is the average distance (in units of standard deviation) of your measurement performance characteristics from the consensus performance. CS is calculated when the number of quantitative values you reported, N_{you} , is at least two and at least six participants reported quantitative values for the analyte.

We define CS as follows:

$$CS = \text{MINIMUM} \left(4, \text{INTEGER} \left(1 + \sqrt{C^2 + AP^2} \right) \right)$$

$$C = \text{Concordance} = \frac{\sum_{i=1}^{N_{you}} \frac{You_i - \text{Median}_i}{NAU_i}}{N_{you}}$$

$$AP = \text{Apparent Precision} = \sqrt{\frac{\sum_{i=1}^{N_{you}} \left(\frac{You_i - \text{Median}_i}{NAU_i} \right)^2}{N_{you} - 1}}$$

NAU = NIST Assigned Uncertainty

For further details, please see

Duewer DL, Kline MC, Sharpless KE, Brown Thomas J, Gary KT. Micronutrients Measurement Quality Assurance Program: Helping participants use interlaboratory comparison exercise results to improve their long-term measurement performance. Anal Chem 1999;71(9):1870-8.

Appendix D. Representative Individualized Report for RR76

Each participant in RR76 received an “Individualized Report” reflecting their reported results. Each report included a detailed analysis for analytes that were assayed by at least five participants. The following analytes met this criterion:

- Total Retinol
- Retinyl Palmitate
- α -Tocopherol
- γ/β -Tocopherol
- Total β -Carotene
- Total α -Carotene
- Total Lycopene
- *trans*-Lycopene
- Total β -Cryptoxanthin
- Total Lutein
- Total Zeaxanthin
- Total Lutein & Zeaxanthin
- Coenzyme Q10

The following fourteen pages are the “Individualized Report” for the analytes evaluated by participant FSV-BB.

Individualized Round Robin LXXVI Report: FSV-BB

Summary

| Analyte | Serum 407 | | | Serum 408 | | | Serum 409 | | | Serum 410 | | | Serum 411 | | |
|-------------------------------|-----------|-------|----|-----------|-------|----|-----------|-------|----|-----------|-------|----|-----------|-------|----|
| | You | NAV | n | You | NAV | n | You | NAV | n | You | NAV | n | You | NAV | n |
| Total Retinol | 0.342 | 0.348 | 29 | 0.477 | 0.497 | 29 | 0.444 | 0.452 | 29 | 0.452 | 0.451 | 28 | 0.438 | 0.456 | 29 |
| Retinyl Palmitate | 0.10 | 0.09 | 5 | 0.1 | 0.0 | 5 | 0.0 | 0.0 | 5 | 0.03 | 0.02 | 5 | 0.03 | 0.02 | 5 |
| α -Tocopherol | 4.62 | 4.31 | 28 | 10.63 | 10.35 | 28 | 7.26 | 6.93 | 28 | 8.20 | 8.00 | 27 | 7.84 | 7.36 | 28 |
| γ/δ -Tocopherol | 1.629 | 1.637 | 16 | 1.408 | 1.409 | 16 | 1.726 | 1.721 | 16 | 1.835 | 1.854 | 15 | 1.793 | 1.767 | 16 |
| δ -Tocopherol | 0.044 | | 2 | 0.083 | | 2 | 0.065 | | 2 | 0.083 | | 2 | 0.049 | | 2 |
| Total β -Carotene | 0.320 | 0.303 | 22 | 0.242 | 0.234 | 22 | 0.042 | 0.046 | 20 | 0.055 | 0.061 | 20 | 0.050 | 0.050 | 20 |
| trans- β -Carotene | 0.304 | 0.295 | 5 | 0.231 | 0.213 | 5 | 0.040 | 0.040 | 5 | 0.054 | 0.054 | 4 | 0.047 | 0.047 | 5 |
| Total cis- β -Carotene | 0.017 | 0.022 | 4 | 0.011 | 0.013 | 4 | 0.002 | 0.004 | 4 | 0.001 | 0.005 | 3 | 0.003 | 0.005 | 4 |
| Total α -Carotene | 0.021 | 0.016 | 14 | 0.032 | 0.032 | 15 | 0.014 | 0.015 | 14 | 0.042 | 0.041 | 14 | 0.029 | 0.027 | 14 |
| Total Lycopene | 0.156 | 0.184 | 15 | 0.543 | 0.585 | 15 | 0.152 | 0.166 | 15 | 0.292 | 0.312 | 14 | 0.214 | 0.240 | 15 |
| trans-Lycopene | 0.088 | 0.092 | 5 | 0.263 | 0.312 | 5 | 0.073 | 0.096 | 5 | 0.133 | 0.174 | 4 | 0.105 | 0.125 | 5 |
| Total β -Cryptoxanthin | 0.053 | 0.056 | 13 | 0.051 | 0.053 | 12 | 0.164 | 0.170 | 13 | 0.022 | 0.023 | 11 | 0.098 | 0.100 | 13 |
| Total α -Cryptoxanthin | 0.022 | | 2 | 0.020 | | 2 | 0.020 | | 2 | 0.012 | | 1 | 0.016 | | 2 |
| Total Lutein | 0.082 | 0.076 | 7 | 0.083 | 0.086 | 7 | 0.073 | 0.077 | 7 | 0.087 | 0.089 | 6 | 0.080 | 0.093 | 7 |
| Total Zeaxanthin | 0.026 | 0.024 | 6 | 0.046 | 0.032 | 6 | 0.049 | 0.041 | 6 | 0.031 | 0.025 | 5 | 0.039 | 0.038 | 6 |
| Total Lutein&Zeaxanthin | 0.108 | 0.097 | 13 | 0.128 | 0.120 | 13 | 0.122 | 0.122 | 13 | 0.119 | 0.101 | 12 | 0.119 | 0.119 | 13 |

You : Your reported values for the listed analytes (micrograms/milliliter)

NAV : NIST Assigned Values, here equal to this RR's median

n : Number of non-NIST laboratories reporting quantitative values for this analyte in this serum




Please check our records against your records. Send corrections and/or updates to...

Micronutrients Measurement Quality Assurance Program
National Institute of Standards and Technology
100 Bureau Drive Stop 8392
Gaithersburg, MD 20899-8392 USA

Tel: (301) 975-3935
Fax: (301) 977-0685
Email: david.duewer@nist.gov

Individualized RR LXXVI Report: FSV-BB

Total Retinol, µg/mL






- 3rd Quartile (75%)
- Median (50%)
- 1st Quartile (25%)
- You, this RR
- You, past RRs
- Expectation
- ▲ You, ≥x, this RR
- △ You, ≥x, past RRs
- + Others, this RR

For details of the construction and interpretation of these plots, see:
 Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

| <u>Serum</u> | <u>Comments</u> | <u>History</u> |
|--------------|--|--|
| #407 | Lyophilized, native, single-source | 28#184, 59#319, 60#327 |
| #408 | Fresh-frozen, native, multi-donor: SRM 968e II | 66#358, 67#364, 69#374, 71#386, 74#399 |
| #409 | Fresh-frozen, native, single-donor | 71#386, 72#390 |
| #410 | Fresh-frozen, native, single-donor | 71#384 |
| #411 | Mixture of (310 mL #409) and (260 mL #410) | 71#385, 73#396 |

Individualized RR LXXVI Report: FSV-BB

Retinyl Palmitate, $\mu\text{g/mL}$



- 3rd Quartile (75%)
- Median (50%)
- 1st Quartile (25%)
- You, this RR
- You, past RRs
- Expectation
- ▲ You, $\geq x$, this RR
- △ You, $\geq x$, past RRs
- + Others, this RR

For details of the construction and interpretation of these plots, see:
 Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

Serum

Comments




History

#407 Lyophilized, native, single-source
 #408 Fresh-frozen, native, multi-donor: SRM 968e II
 #409 Fresh-frozen, native, single-donor
 #410 Fresh-frozen, native, single-donor
 #411 Mixture of (310 mL #409) and (260 mL #410)

28#184, 59#319, 60#327
 66#358, 67#364, 69#374, 71#386, 74#399
 71#386, 72#390
 71#384
 71#385, 73#396

Individualized RR LXXVI Report: FSV-BB

α-Tocopherol, µg/mL






- 3rd Quartile (75%)
 ● You, this RR
▲ You, ≥x, this RR
- Median (50%)
 ○ You, past RRs
△ You, ≥x, past RRs
+ Others, this RR
- 1st Quartile (25%)
 — Expectation

For details of the construction and interpretation of these plots, see:
 Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

| <u>Serum</u> | <u>Comments</u> | <u>History</u> |
|--------------|--|--|
| #407 | Lyophilized, native, single-source | 28#184, 59#319, 60#327 |
| #408 | Fresh-frozen, native, multi-donor: SRM 968e II | 66#358, 67#364, 69#374, 71#386, 74#399 |
| #409 | Fresh-frozen, native, single-donor | 71#386, 72#390 |
| #410 | Fresh-frozen, native, single-donor | 71#384 |
| #411 | Mixture of (310 mL #409) and (260 mL #410) | 71#385, 73#396 |

Individualized RR LXXVI Report: FSV-BB

γ/β -Tocopherol, $\mu\text{g/mL}$






- 3rd Quartile (75%)
- Median (50%)
- 1st Quartile (25%)
- You, this RR
- You, past RRs
- Expectation
- You, $\geq x$, this RR
- You, $\geq x$, past RRs
- Others, this RR

For details of the construction and interpretation of these plots, see:
 Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

| <u>Serum</u> | <u>Comments</u> | <u>History</u> |
|--------------|--|--|
| #407 | Lyophilized, native, single-source | 28#184, 59#319, 60#327 |
| #408 | Fresh-frozen, native, multi-donor: SRM 968e II | 66#358, 67#364, 69#374, 71#386, 74#399 |
| #409 | Fresh-frozen, native, single-donor | 71#386, 72#390 |
| #410 | Fresh-frozen, native, single-donor | 71#384 |
| #411 | Mixture of (310 mL #409) and (260 mL #410) | 71#385, 73#396 |

Individualized RR LXXVI Report: FSV-BB

Total β -Carotene, $\mu\text{g/mL}$






- 3rd Quartile (75%)
- Median (50%)
- 1st Quartile (25%)
- You, this RR
- You, past RRs
- Expectation
- You, $\geq x$, this RR
- You, $\geq x$, past RRs
- Others, this RR

For details of the construction and interpretation of these plots, see:
 Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

| <u>Serum</u> | <u>Comments</u> | <u>History</u> |
|--------------|--|--|
| #407 | Lyophilized, native, single-source | 28#184, 59#319, 60#327 |
| #408 | Fresh-frozen, native, multi-donor: SRM 968e II | 66#358, 67#364, 69#374, 71#386, 74#399 |
| #409 | Fresh-frozen, native, single-donor | 71#386, 72#390 |
| #410 | Fresh-frozen, native, single-donor | 71#384 |
| #411 | Mixture of (310 mL #409) and (260 mL #410) | 71#385, 73#396 |

Individualized RR LXXVI Report: FSV-BB

Total α -Carotene, $\mu\text{g/mL}$






- 3rd Quartile (75%)
 ● You, this RR
▲ You, $\geq x$, this RR
- Median (50%)
 You, past RRs
 You, $\geq x$, past RRs
+ Others, this RR
- 1st Quartile (25%)
 — Expectation

For details of the construction and interpretation of these plots, see:
 Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

| Serum | Comments | History |
|-------|--|--|
| #407 | Lyophilized, native, single-source | 28#184, 59#319, 60#327 |
| #408 | Fresh-frozen, native, multi-donor: SRM 968e II | 66#358, 67#364, 69#374, 71#386, 74#399 |
| #409 | Fresh-frozen, native, single-donor | 71#386, 72#390 |
| #410 | Fresh-frozen, native, single-donor | 71#384 |
| #411 | Mixture of (310 mL #409) and (260 mL #410) | 71#385, 73#396 |

Individualized RR LXXVI Report: FSV-BB

Total Lycopene, $\mu\text{g/mL}$






- 3rd Quartile (75%)
 You, this RR
 You, $\geq x$, this RR
- Median (50%)
 You, past RRs
 You, $\geq x$, past RRs
 Others, this RR
- 1st Quartile (25%)
 Expectation

For details of the construction and interpretation of these plots, see:
 Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

| Serum | Comments | History |
|-------|--|--|
| #407 | Lyophilized, native, single-source | 28#184, 59#319, 60#327 |
| #408 | Fresh-frozen, native, multi-donor: SRM 968e II | 66#358, 67#364, 69#374, 71#386, 74#399 |
| #409 | Fresh-frozen, native, single-donor | 71#386, 72#390 |
| #410 | Fresh-frozen, native, single-donor | 71#384 |
| #411 | Mixture of (310 mL #409) and (260 mL #410) | 71#385, 73#396 |

Individualized RR LXXVI Report: FSV-BB

trans-Lycopene, $\mu\text{g/mL}$






- 3rd Quartile (75%)
- Median (50%)
- 1st Quartile (25%)
- You, this RR
- You, past RRs
- Expectation
- You, $\geq x$, this RR
- You, $\geq x$, past RRs
- Others, this RR

For details of the construction and interpretation of these plots, see:
 Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

| <u>Serum</u> | <u>Comments</u> | <u>History</u> |
|--------------|--|--|
| #407 | Lyophilized, native, single-source | 28#184, 59#319, 60#327 |
| #408 | Fresh-frozen, native, multi-donor: SRM 968e II | 66#358, 67#364, 69#374, 71#386, 74#399 |
| #409 | Fresh-frozen, native, single-donor | 71#386, 72#390 |
| #410 | Fresh-frozen, native, single-donor | 71#384 |
| #411 | Mixture of (310 mL #409) and (260 mL #410) | 71#385, 73#396 |

Individualized RR LXXVI Report: FSV-BB

Total β -Cryptoxanthin, $\mu\text{g/mL}$






- 3rd Quartile (75%)
- Median (50%)
- 1st Quartile (25%)
- You, this RR
- You, past RRs
- Expectation
- You, $\geq x$, this RR
- You, $\geq x$, past RRs
- Others, this RR

For details of the construction and interpretation of these plots, see:
 Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

| <u>Serum</u> | <u>Comments</u> | <u>History</u> |
|--------------|--|--|
| #407 | Lyophilized, native, single-source | 28#184, 59#319, 60#327 |
| #408 | Fresh-frozen, native, multi-donor: SRM 968e II | 66#358, 67#364, 69#374, 71#386, 74#399 |
| #409 | Fresh-frozen, native, single-donor | 71#386, 72#390 |
| #410 | Fresh-frozen, native, single-donor | 71#384 |
| #411 | Mixture of (310 mL #409) and (260 mL #410) | 71#385, 73#396 |

Individualized RR LXXVI Report: FSV-BB

Total Lutein, $\mu\text{g/mL}$






- 3rd Quartile (75%)
- Median (50%)
- 1st Quartile (25%)
- You, this RR
- You, past RRs
- Expectation
- You, $\geq x$, this RR
- You, $\geq x$, past RRs
- Others, this RR

For details of the construction and interpretation of these plots, see:
 Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

| Serum | Comments | History |
|-------|--|--|
| #407 | Lyophilized, native, single-source | 28#184, 59#319, 60#327 |
| #408 | Fresh-frozen, native, multi-donor: SRM 968e II | 66#358, 67#364, 69#374, 71#386, 74#399 |
| #409 | Fresh-frozen, native, single-donor | 71#386, 72#390 |
| #410 | Fresh-frozen, native, single-donor | 71#384 |
| #411 | Mixture of (310 mL #409) and (260 mL #410) | 71#385, 73#396 |

Individualized RR LXXVI Report: FSV-BB

Total Zeaxanthin, $\mu\text{g/mL}$






- 3rd Quartile (75%)
- Median (50%)
- 1st Quartile (25%)
- You, this RR
- You, past RRs
- Expectation
- You, $\geq x$, this RR
- You, $\geq x$, past RRs
- Others, this RR

For details of the construction and interpretation of these plots, see:
 Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

| Serum | Comments | History |
|-------|--|--|
| #407 | Lyophilized, native, single-source | 28#184, 59#319, 60#327 |
| #408 | Fresh-frozen, native, multi-donor: SRM 968e II | 66#358, 67#364, 69#374, 71#386, 74#399 |
| #409 | Fresh-frozen, native, single-donor | 71#386, 72#390 |
| #410 | Fresh-frozen, native, single-donor | 71#384 |
| #411 | Mixture of (310 mL #409) and (260 mL #410) | 71#385, 73#396 |

Individualized RR LXXVI Report: FSV-BB

Total Lutein&Zeaxanthin, $\mu\text{g/mL}$




For details of the construction and interpretation of these plots, see:
 Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

| Serum | Comments | History |
|-------|--|--|
| #407 | Lyophilized, native, single-source | 28#184, 59#319, 60#327 |
| #408 | Fresh-frozen, native, multi-donor: SRM 968e II | 66#358, 67#364, 69#374, 71#386, 74#399 |
| #409 | Fresh-frozen, native, single-donor | 71#386, 72#390 |
| #410 | Fresh-frozen, native, single-donor | 71#384 |
| #411 | Mixture of (310 mL #409) and (260 mL #410) | 71#385, 73#396 |

Individualized Round Robin LXXVI Report: FSV-BB

Graphical Comparability Summary




D15

Appendix E. Shipping Package Inserts for RR41

The following three items were included in each package shipped to an RR41 participant:

- Cover letter
- Analysis of Control Materials and Test Samples Datasheet
- Packing List and Shipment Receipt Confirmation Form

The cover letter and datasheet were enclosed in a sealed waterproof bag along with the samples themselves. This bag was labeled:



The packing list was placed at the top of the shipping box, between the cardboard covering and the foam insulation.



February 10, 2014

Dear Colleague:

The samples within this package constitute Vitamin C Round Robin 41 (RR41) of the 2014 Micronutrients Measurement Quality Assurance Program. RR41 consists of one vial each of four frozen serum *test samples* (#411, #412 #413, and #414) and one vial each of two frozen *control sera* (CS#3 and CS#4). These materials are in sealed ampoules. They were prepared by adding equal volumes of 10% MPA to spiked human serum. We have checked the samples for stability and homogeneity. Only total ascorbic acid is stable. While these samples contain some dehydroascorbic acid, its content is variable. Therefore, only total ascorbic acid should be analyzed and reported.

Please use the *control sera* to validate the performance of your measurement system before you analyze the *test samples*. The target value for CS#3 is $(15.5 \pm 1.6; 13.9 \text{ to } 17.1) \mu\text{mol/L}$ and the target for CS#4 is $(46.1 \pm 4.6; 41.5 \text{ to } 50.7) \mu\text{mol/L}$. We expect your results for both of these controls to be within this $\pm 10\%$ target range. If your results are significantly outside this range, your analysis system may not be suited to the analysis of MPA-preserved samples. In this case, please do **not** proceed to the analysis of the *test samples* but contact us at jbthomas@nist.gov or 301-975-3120.

The *test samples* and *control sera* should be defrosted by warming at 20 °C for not more than 10 min otherwise some irreversible degradation may occur. Please be aware that sample contact with any oxidant-contaminated surface (vials, glassware, etc.) may degrade your measurement system's performance (SA Margolis and E Park, "Stability of Ascorbic Acid in Solutions in Autosampler Vials", *Clinical Chemistry* 2001, 47(8), 1463-1464). You should suspect such degradation if you observe unusually large variation in replicate analyses.

Please measure the total ascorbic acid in each ampoule in duplicate, reporting in units of $\mu\text{mol}/(\text{L sample solution})$ rather than $\mu\text{mol}/(\text{L serum used to prepare the sample})$. Please email (david.duewer@nist.gov) or fax (301-977-0685) your results to us as soon as possible but no later than **September 15, 2014**.

Please report your results by e-mail to david.duewer@nist.gov or fax to 301-977-0685. If you have questions or comments regarding the studies, please contact us at 301-975-3120 (Jeanice); jbthomas@nist.gov or 301-975-3935 (Dave); david.duewer@nist.gov.

Sincerely,

Jeanice B. Thomas, M.B.A.
Research Chemist
Chemical Sciences Division
Material Measurement Laboratory

David L. Duewer, Ph.D.
Research Chemometrician
Chemical Sciences Division
Material Measurement Laboratory

Enclosure: RR41 Report Form for Control and Test Sample Analyses

Participant #: _____

Date: _____

Vitamin C Round Robin 41
NIST Micronutrient Measurement Quality Assurance Program

Analysis of Control Materials and Test Samples

| Sample | Replicate 1 | Replicate 2 | Units |
|--------------------|--------------------|--------------------|--|
| Control serum CS#3 | | | $\mu\text{mol/L}$ of Sample <i>Target: (15.5 \pm 1.6) $\mu\text{mol/L}$</i> |
| Control serum CS#4 | | | $\mu\text{mol/L}$ of Sample <i>Target: (46.1 \pm 4.6) $\mu\text{mol/L}$</i> |
| Test sample #411 | | | $\mu\text{mol/L}$ of Sample |
| Test sample #412 | | | $\mu\text{mol/L}$ of Sample |
| Test sample #413 | | | $\mu\text{mol/L}$ of Sample |
| Test sample #414 | | | $\mu\text{mol/L}$ of Sample |

Were samples frozen upon receipt? Yes | No

Analysis method: HPLC-EC | HPLC-Fluor DAB | HPLC-OPD | HPLC-UV | AO-OPD | Other
If "Other", please describe:

Nature of samples you typically analyze: native | MPA-preserved | DTT-preserved | Other
If "Other", please describe:

COMMENTS:

Please return by **September 15, 2014**

MMQAP
100 Bureau Drive, Stop 8392
Gaithersburg, MD 20899-8392

Fax: 301-977-0685
Email: david.duewer@nist.gov

Participant #: _____

Date: _____

Vitamin C Round Robin 41
NIST Micronutrients Measurement Quality Assurance Program
Packing List and Shipment Receipt Confirmation Form

This box contains one vial each of the following **six** VitC M²QAP samples:

| Label | Form |
|-----------|-----------------------------------|
| VitC #411 | Liquid frozen (1:1 serum:10% MPA) |
| VitC #412 | Liquid frozen (1:1 serum:10% MPA) |
| VitC #413 | Liquid frozen (1:1 serum:10% MPA) |
| VitC #414 | Liquid frozen (1:1 serum:10% MPA) |
| CS#3 | Liquid frozen (1:1 serum:10% MPA) |
| CS#4 | Liquid frozen (1:1 serum:10% MPA) |

- Please**
- 1) Open the pack immediately
 - 2) Check that it contains one vial each of the above samples
 - 3) Check if the samples arrived frozen
 - 4) Store the samples at -20 °C or below until analysis
 - 5) Email (david.duewer@nist.gov) or fax (301-977-0685) us the following information:

1) Date this shipment arrived: _____

2) Are all of the vials intact? Yes | No
If "No", which one(s) were damaged?

3) Was there any dry-ice left in cooler? Yes | No

4) Did the samples arrive frozen? Yes | No

5) At what temperature are you storing the samples? _____ °C

Your prompt return of this information is appreciated.

The M²QAP Gang

Appendix F. Final Report for RR410

The following three pages are the final report for RR41 as provided to all participants:

- Cover letter.
- An information sheet that:
 - describes the contents of the “All-Lab” report,
 - describes the content of the “Individualized” report,
 - describes the nature of the test samples and details their previous distributions, if any, and
 - summarizes aspects of the study that we believe may be of interest to the participants.

October 3, 2014



UNITED STATES DEPARTMENT OF COMMERCE
National Institute of Standards and Technology
Gaithersburg, Maryland 20899-8410

Dear Colleague:

Enclosed is the summary report of the results for Round Robin 41 (RR41) for the measurement of total ascorbic acid (TAA, ascorbic acid plus dehydroascorbic acid) in human serum. Included in this report are a summary of data for all laboratories and an individualized summary of your laboratory's measurement performance. The robust median is used to estimate the consensus value for all samples, the "adjusted median absolute deviation from the median" (MADe) is used to estimate the expected standard deviation, and we estimate the coefficient of variation (CV) as $100 \times \text{MADe} / \text{median}$.

RR41 consisted of one vial each of four test samples (#411, #412, #413, and #414) and one vial each of two control samples (CS#3 and CS#4). Both the test and control samples are 1:1 mixtures of serum and 10 % metaphosphoric acid augmented with high-purity ascorbic acid. Details regarding the samples can be found in the enclosed report.

If you have concerns regarding your laboratory's performance, we suggest that you obtain and analyze a unit of Standard Reference Material (SRM) 970 Vitamin C in Frozen Human Serum. SRM 970 can be purchased from the NIST SRM Program at www.nist.gov/srm; phone: 301-975-6776; fax: 301-948-3730. If your measured values do not agree with the certified values, we suggest that you contact us for consultation.

If you returned your intent-to-participate form for the 2015 NIST Micronutrients Measurement Quality Assurance Program (MMQAP), you should have received a confirmation receipt. Please notify us if you have not received your confirmation receipt.

Laboratories participating in the upcoming program will receive samples for the two vitamin C in serum studies (RR42 and RR43) in February 2015. Please note that we will ship the samples for both studies at the same time in February. Results will be due in May 2015 for the first study and in September 2015 for the second study. We will send you a reminder in late July 2015 about the reporting deadline for the second study. Please contact us immediately if this schedule is problematic for your laboratory.

If you have questions or concerns regarding this report, please contact David Duewer at david.duewer@nist.gov or me at jbthomas@nist.gov, 301-975-3120, or fax: 301-977-0685.

Sincerely,

Jeanice Brown Thomas, M.B.A.
Research Chemist
Chemical Sciences Division
Material Measurement Laboratory

David L. Duewer, Ph.D.
Research Chemometrician
Chemical Sciences Division
Material Measurement Laboratory

Enclosures

The NIST MMQAP Vitamin C Round Robin 41 (RR41) report consists of:

| Page | “Individualized” Report |
|------|--|
| 1 | Summary of your reported values for the two serum control and four serum test samples. |
| 2 | Graphical summary of your RR41 measurements. |

| Page | “All-Lab” Report |
|------|--|
| 1 | A tabulation of results and summary statistics for total ascorbic acid [TAA] in the RR41 control and test samples. Results and summary statistics are also presented for the test samples calibrated to the results for the control samples using both 2-point proportional and linear models. |

Serum-Based Samples. Two serum controls and four test samples were distributed in RR41.

- CS#3 Material ampouled in 2009 containing $15.4 \pm 0.4 \mu\text{mol/L}$ [TAA]
- CS#4 Material ampouled in 2009 containing $46.2 \pm 1.2 \mu\text{mol/L}$ [TAA]
- S41:1 Ampouled in late 2009, previously distributed in RRs 34, 36 (as two samples), 38 and 40
- S41:2 Ampouled in late 2009, previously distributed in RRs 32, 35, 36 and 38
- S41:3 Ampouled in late 2009, previously distributed in RRs 32, 33, 35, 38 and 40
- S41:4 SRM 970 level 1, ampouled in mid-1998, previously distributed as a test sample in RRs 11 to 16, 19, 20 23, 25, 29, 31, 34, 37 and 39

Results.

- 1) The reported [TAA] contents of the two control sera (CS#3 and CS#4) are unchanged from the values estimated for these materials when they were distributed as unknowns. The expected [TAA] content and inter-participant standard deviations are estimated with the robust median and adjusted median absolute deviation (eSD) statistics.
- 2) There is no evidence for any significant change in the [TAA] level for any of the four test materials.
- 3) The results for two control sera with well separated [TAA] levels enable calibration of the reported results for the unknowns to the both proportional and linear models. The proportional model is:

$$[\text{TAA}]_{\text{reportedCS}} = b \times [\text{TAA}]_{\text{referenceCS}}$$

where $[\text{TAA}]_{\text{reportedCS}}$ are the reported values for the two control sera, $[\text{TAA}]_{\text{referenceCS}}$ are the established reference values for these materials, and b is estimated using least-squares regression. The inverse model for estimating calibrated values for unknown samples is then:

$$[\text{TAA}]_{\text{calibrated}} = [\text{TAA}]_{\text{reported}} / b.$$

The linear model and its inverse are:

$$[\text{TAA}]_{\text{reportedCS}} = a + b \times [\text{TAA}]_{\text{referenceCS}}; \quad [\text{TAA}]_{\text{calibrated}} = ([\text{TAA}]_{\text{reported}} - a) / b.$$

where the a and b parameters are defined by the line between the {reference, reported} values for the two control sera.

Figure 1 displays eSD as a function of the Median values for the test samples distributed in RR34 through RR41 where the CS#3 and CS#4 were distributed as either test or control samples.




Figure 1: Estimated Standard Deviation as a Function of Median Value

Each symbol represents the summary statistics for one of the test samples distributed in RR34 through RR41. The solid red circles represent the results as they were reported (i.e., uncalibrated); the red line represents a “best fit” functional relationship between the eSD and the median. The open blue squares and blue line represent the reported test-sample results after calibration to the control samples using the proportional model. The open green diamonds and green line represent the results after calibration to the linear model.

The relationship between the eSD and the median values for the “As Reported” results is adequately described as a constant coefficient of variation, $eCV = 100 \times eSD / \text{Median}$, of 7.1 %. The best-fit relationship for the results calibrated to the proportional model is more complex, with a fairly constant component of 0.80 $\mu\text{mol/L}$ for [TAA] levels of 20 $\mu\text{mol/L}$ or less and a constant eCV of 3.0 % above 20 $\mu\text{mol/L}$. The best-fit relationship with the linear model calibration is a constant eSD of 1.0 $\mu\text{mol/L}$ regardless of [TAA].

Since calibration using the proportional model tends to increase the variability for the lower [TAA] samples but does not completely stabilize it at higher levels, the proportional calibration model appears to be inferior to the linear model. While calibration to the two control samples dramatically reduces interlaboratory variability for the higher [TAA] materials, it increases variability at the lower [TAA] levels.

The addition of the RR41 results to those from the previous studies do not significantly impact the above analysis. Consequently, we will not distribute control materials in the 2015 vitamin C studies.

Appendix G. “All-Lab Report” for RR41

The following two pages are the “All-Lab Report” for RR41 as provided to all participants, with the following exceptions:

- the participant identifiers (Lab) have been altered.
- the order in which the participant results are listed has been altered.
- the Legend page has been added

The data summary in the “All-Lab Report” has been altered to ensure confidentiality of identification codes assigned to laboratories.

Micronutrients Measurement Quality Assurance Program for Total Ascorbic Acid "Round Robin" 41 - Fall 2014

| Lab | Date | Samples | | | | Calibrated Results: [TAA] = TAA/b | | | | Calibrated Results: [TAA]' = (TAA-a)/b | | | | | | | | |
|---------|----------|-------------------------------------|------|-------|-------|-----------------------------------|-------|--------|--------|--|--------|------------|------|------|------|------|------|------|
| | | Total Ascorbic Acid ([TAA]), μmol/L | | | | [TAA]', μmol/L | | | | [TAA]', μmol/L | | | | | | | | |
| | | CS#3 | CS#4 | S41:1 | S41:2 | S41:3 | S41:4 | S41:1' | S41:2' | S41:3' | S41:4' | Parameters | | | | | | |
| VC-MB | 14/08/14 | 14.2 | 45.9 | 57.6 | 30.7 | 22.7 | 8.5 | 0.99 | 57.9 | 30.9 | 22.8 | 8.6 | 1.03 | -1.5 | 57.1 | 31.2 | 23.4 | 9.7 |
| VC-MC | 12/09/14 | 15.1 | 44.8 | 55.6 | 29.7 | 23.1 | 7.5 | 0.98 | 56.9 | 30.4 | 23.6 | 7.7 | 0.97 | 0.5 | 57.1 | 30.3 | 23.5 | 7.3 |
| VC-MG | 22/08/14 | 15.4 | 48.8 | 60.8 | 29.8 | 23.5 | 8.2 | 1.06 | 57.5 | 28.2 | 22.2 | 7.8 | 1.09 | -1.2 | 56.9 | 28.5 | 22.7 | 8.7 |
| VC-MH | 14/08/14 | 15.7 | 44.1 | 53.3 | 29.4 | 22.4 | 8.2 | 0.97 | 55.1 | 30.4 | 23.1 | 8.4 | 0.93 | 1.5 | 55.8 | 30.0 | 22.4 | 7.1 |
| VC-MI | 15/09/14 | 14.8 | 45.9 | 57.5 | 31.4 | 23.7 | 9.3 | 1.00 | 57.7 | 31.5 | 23.7 | 9.3 | 1.01 | -0.6 | 57.4 | 31.6 | 24.0 | 9.8 |
| VC-MJ | 09/09/14 | 18.8 | 49.0 | 66.3 | 38.0 | 30.4 | 9.1 | 1.08 | 61.1 | 35.0 | 28.0 | 8.4 | 0.98 | 3.9 | 63.5 | 34.7 | 27.0 | 5.3 |
| VC-MN | 05/08/14 | 15.1 | 42.2 | 52.5 | 28.6 | 19.3 | 7.1 | 0.93 | 56.8 | 30.9 | 20.8 | 7.6 | 0.88 | 1.6 | 57.6 | 30.5 | 20.0 | 6.2 |
| VC-NM | 12/09/14 | 13.6 | 43.5 | 54.9 | 28.9 | 21.6 | 8.7 | 0.94 | 58.3 | 30.7 | 22.9 | 9.2 | 0.97 | -1.3 | 57.6 | 30.9 | 23.4 | 10.2 |
| VC-NX | 15/09/14 | 13.9 | 49.2 | 59.9 | 32.7 | 23.1 | 7.0 | 1.06 | 56.8 | 30.9 | 21.9 | 6.6 | 1.15 | -3.6 | 55.2 | 31.5 | 23.2 | 9.2 |
| N | | 9 | 9 | 9 | 9 | 9 | 9 | | 9 | 9 | 9 | 9 | | | 9 | 9 | 9 | 9 |
| Average | | 15.2 | 45.9 | 57.6 | 31.0 | 23.3 | 8.2 | | 57.5 | 31.0 | 23.2 | 8.2 | | | 57.6 | 31.0 | 23.3 | 8.2 |
| SD | | 1.5 | 2.6 | 4.3 | 2.9 | 3.0 | 0.8 | | 1.6 | 1.8 | 2.0 | 0.8 | | | 2.3 | 1.7 | 1.8 | 1.7 |
| Min | | 13.6 | 42.2 | 52.5 | 28.6 | 19.3 | 7.0 | | 55.1 | 28.2 | 20.8 | 6.6 | | | 55.2 | 28.5 | 20.0 | 5.3 |
| %25 | | 14.2 | 44.1 | 54.9 | 29.4 | 22.4 | 7.5 | | 56.8 | 30.4 | 22.2 | 7.7 | | | 56.9 | 30.3 | 22.7 | 7.1 |
| Median | | 15.1 | 45.9 | 57.5 | 29.8 | 23.1 | 8.2 | | 57.5 | 30.9 | 22.9 | 8.4 | | | 57.1 | 30.9 | 23.4 | 8.7 |
| %75 | | 15.4 | 48.8 | 59.9 | 31.4 | 23.5 | 8.7 | | 57.9 | 30.9 | 23.6 | 8.6 | | | 57.6 | 31.5 | 23.5 | 9.7 |
| Max | | 18.8 | 49.2 | 66.3 | 38.0 | 30.4 | 9.3 | | 61.1 | 35.0 | 28.0 | 9.3 | | | 63.5 | 34.7 | 27.0 | 10.2 |
| eSD | | 0.9 | 3.7 | 4.0 | 1.4 | 0.8 | 1.1 | | 1.1 | 0.7 | 1.1 | 1.0 | | | 0.7 | 0.9 | 0.8 | 2.0 |
| eCV | | 6 | 8 | 7 | 5 | 4 | 13 | | 2 | 2 | 5 | 12 | | | 1 | 3 | 3 | 23 |

Micronutrients Measurement Quality Assurance Program for Total Ascorbic Acid "Round Robin" 41 - Summer 2014

Legend

| Term | Definition |
|----------|--|
| Lab | Participant code |
| Date | Date results received at NIST |
| <i>b</i> | Slope and Intercept of the line connecting the expected values |
| <i>a</i> | for control samples CS#3 and CS#4 with the results reported by each participant |
| N | Number of quantitative values reported for this analyte |
| Average | Mean of the reported quantitative values |
| SD | Standard deviation of the reported quantitative values |
| Min | Minimum quantitative value reported |
| %25 | First quartile of the reported quantitative values |
| Median | Median (second quartile) of the reported quantitative values |
| %75 | Third quartile of the reported quantitative values |
| Max | Maximum quantitative value reported |
| eSD | Robust standard deviation, estimated using the adjusted median absolute deviation from the median (MADe) |
| eCV | Robust Coefficient of Variation, estimated as $100 \cdot eSD / \text{Median}$ |

Appendix H. Representative “Individualized Report” for RR41

Each participant in RR41 received an “Individualized Report” reflecting their reported results. The following three pages are the “Individualized Report” for participant “VC-MB”.

Vitamin C "Round Robin" 41 Report: Participant VC-MB

| Date | RR | Sample | [TAA] mmol/Lsample | | | | | N | Mean | SD _{repeat} | SD _{reprod} |
|----------|----|--------|--------------------|------------------|------------------|------|-------------------|---|------|----------------------|----------------------|
| | | | Rep ₁ | Rep ₂ | F _{adj} | Mean | SD _{dup} | | | | |
| 01/14/11 | 34 | S34:4 | 56.8 | 57.3 | 1.0 | 57.0 | 0.4 | 6 | 57.5 | 0.6 | 1.3 |
| 03/07/12 | 36 | S36:1 | 57.8 | 56.8 | 1.0 | 57.3 | 0.7 | | | | |
| 03/07/12 | 36 | S36:4 | 56.8 | 55.2 | 1.0 | 56.0 | 1.1 | | | | |
| 02/27/13 | 38 | S38:4 | 57.3 | 56.8 | 1.0 | 57.0 | 0.4 | | | | |
| 02/24/14 | 40 | S40:4 | 59.9 | 59.9 | 1.0 | 59.9 | 0.0 | | | | |
| 08/14/14 | 41 | S41:1 | 57.3 | 57.8 | 1.0 | 57.6 | 0.4 | | | | |
| 01/13/10 | 32 | S32:3 | 30.5 | 31.0 | 1.0 | 30.7 | 0.4 | 5 | 30.9 | 0.5 | 0.6 |
| 06/13/11 | 35 | S35:3 | 32.0 | 31.5 | 1.0 | 31.7 | 0.4 | | | | |
| 03/07/12 | 36 | S36:2 | 31.5 | 30.5 | 1.0 | 31.0 | 0.7 | | | | |
| 02/27/13 | 38 | S38:3 | 29.9 | 30.5 | 1.0 | 30.2 | 0.4 | | | | |
| 08/14/14 | 41 | S41:2 | 30.5 | 31.0 | 1.0 | 30.7 | 0.4 | | | | |
| 01/13/10 | 32 | S32:2 | 22.2 | 22.7 | 1.0 | 22.5 | 0.4 | 6 | 22.8 | 0.6 | 0.7 |
| 07/23/10 | 33 | S33:4 | 23.2 | 22.7 | 1.0 | 23.0 | 0.4 | | | | |
| 06/13/11 | 35 | S35:2 | 23.7 | 23.7 | 1.0 | 23.7 | 0.0 | | | | |
| 02/27/13 | 38 | S38:2 | 21.2 | 22.2 | 1.0 | 21.7 | 0.7 | | | | |
| 02/24/14 | 40 | S40:3 | 23.7 | 22.7 | 1.0 | 23.2 | 0.7 | | | | |
| 08/14/14 | 41 | S41:3 | 22.2 | 23.2 | 1.0 | 22.7 | 0.7 | | | | |
| 09/25/98 | 11 | S11:1 | 25.0 | 25.0 | 0.5 | 12.5 | 0.0 | | | | |
| 02/26/99 | 12 | S12:1 | 18.0 | 18.0 | 0.5 | 9.0 | 0.0 | | | | |
| 03/03/00 | 13 | S13:1 | 24.0 | 24.0 | 0.5 | 12.0 | 0.0 | | | | |
| 03/26/01 | 14 | S14:3 | 19.6 | 19.6 | 0.5 | 9.8 | 0.0 | | | | |
| 09/05/01 | 15 | S15:1 | 25.8 | 23.7 | 0.5 | 12.4 | 0.7 | | | | |
| 02/08/02 | 16 | S16:1 | 18.7 | 18.7 | 0.5 | 9.4 | 0.0 | | | | |
| 05/01/03 | 19 | S19:4 | 19.6 | 19.6 | 0.5 | 9.8 | 0.0 | | | | |
| 03/01/04 | 20 | S20:3 | 7.8 | 10.9 | 1.0 | 9.3 | 2.2 | | | | |
| 05/25/05 | 23 | S23:4 | 7.7 | 7.7 | 1.0 | 7.7 | 0.0 | | | | |
| 05/24/06 | 25 | S25:1 | 8.8 | 8.8 | 1.0 | 8.8 | 0.0 | | | | |
| 06/20/08 | 29 | S29:2 | 8.3 | 7.7 | 1.0 | 8.0 | 0.4 | | | | |
| 08/05/09 | 31 | S31:3 | 8.8 | 8.3 | 1.0 | 8.5 | 0.4 | | | | |
| 01/14/11 | 34 | S34:1 | 7.7 | 7.7 | 1.0 | 7.7 | 0.0 | | | | |
| 08/06/12 | 37 | S37:1 | 8.8 | na | 1.0 | 8.8 | | | | | |
| 08/01/13 | 39 | S39:1 | 8.3 | 7.7 | 1.0 | 8.0 | 0.4 | | | | |
| 08/14/14 | 41 | S41:4 | 8.8 | 8.3 | 1.0 | 8.5 | 0.4 | | | | |




Please check our records against your records. Send corrections and/or updates to...

Micronutrients Measurement Quality Assurance Program
National Institute of Standards and Technology

Fax: (301) 977-0685
Email: david.duewer@nist.gov

Vitamin C "Round Robin" 41 Report: Participant VC-MB

Total Ascorbic Acid, $\mu\text{mol/mL}$



For details of the construction and interpretation of these plots, see:
 Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

Sample

Comments

- S41:1 Prepared 2009; distributed RRs 34,36(dups),38,40
- S41:2 Prepared 2009; distributed RRs 32,33,35,38
- S41:3 Prepared 2009; distributed RRs 32,33,35,38,40
- S41:4 SRM970 Lv I; prepared 1998; distributed as unknowns RRs 11 - 16,19,20,23,25,29,31,34,37,39